ClinicalTrials.gg
CompletedNCT05580003Updated Nov 21, 2024Results posted

A Study to Learn Safety and Blood Levels of PF-07817883 in Healthy People

A Phase 1 interventional study of PF-07817883 and Placebo in Healthy, sponsored by Pfizer. Completed at 2 sites in 2 countries. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-11-21.

Sponsored by Pfizer · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
94
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 69 studies in COVID-19 by Pfizer — 4 open to participants now, 10 under way, 3 of them phase 3. COVID-19 · Pfizer.

Enrollment
14th of 41
94 · median 20
Started
2022
with 17 others
Phase 1
25 of 69
none open now
Registered
36th of 69
by date

Among the 69 studies in COVID-19 by Pfizer, this one is the 14th largest by enrollment of the 41 interventional ones that give a count, is one of 18 that started in 2022, is one of 25 in phase 1, and was the 36th registered.

COVID-19

7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.

Browse COVID-19 studies →

Open to participants now

4 of the 69 studies in COVID-19 by Pfizer are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 69 studies in COVID-19 by Pfizer, or all of them as a file.
02

Study summary

The purpose of this clinical trial is to learn if the study medicine (called PF-07817883) is safe and how it goes in and out of the body in healthy people. PF-07817883 is for the potential treatment of COVID-19. Participants will take PF-07817883 by mouth up to 2 times a day. This study may also evaluate how much PF-07817883 gets into the body when taken as pill. We may study if people's diets can affect this study medicine. We may also examine how PF-07817883 is processed and removed by the human body. Finally, we may look into if PF-07817883 has potential to interact with midazolam.

Read the detailed description

Combined 6-part study. Part-1: Single Ascending dose Part-2: Multiple Ascending Dose Part-3: Relative bioavailability and food effect Part-4: Metabolism and Excretion Part-5: Drug-drug interaction with midazolam Part-6: Supratherapeutic exposure Part-1,2 and 6 are double blind, sponsor open and Part-3,4 and 5 are open label study.

03

Conditions studied

  • Healthy

Browse trials for

Keywords

  • Oral Antiviral
  • COVID-19
  • Protease Inhibitor
  • Mpro
  • PF-07817883
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male or female subjects between ages of 18-60 years. Male only in part-4.
  • (BMI) of 17.5 to 30.5kg/m2; and a total body weight >50kg (110lbs). A body weight of >45 kg may be considered in selected cases.
  • Japanese subjects who have four Japanese biologic grandparents born in Japan
  • Chinese participants who were born in mainland China and both parents are of the Chinese descent.

Exclusion criteria

Exclusion Criteria:

  • Evidence or history of hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing)
  • Any condition possibly affecting drug absorption (eg, gastrectomy, cholecystectomy, intestinal resection).
  • Positive test result for SARS-CoV-2 infection at the time of screening or Day-1.
  • Have received COVID-19 vaccine within 7 days before screening or have received only one of the 2 required doses of COVID-19 vaccine
  • Use of tobacco or nicotine containing products in excess of the equivalents of 5 cigarettes per day or 2 chews of tobacco per day
  • Use of prescription or nonprescription drugs and dietary and herbal supplements within 28 days or 5 half lives (whichever is longer) prior to the first dose of study intervention.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
94 participants (actual)

Study arms

  • Experimental
    PF-07817883 Dose 1 in PART-1

    Drug: PF-07817883

  • Experimental
    PF-07817883 Dose 2 in PART-1

    Drug: PF-07817883

  • Experimental
    PF-07817883 Dose 3 in PART-1

    Drug: PF-07817883

  • Experimental
    PF-07817883 Dose 4 in PART-1

    Drug: PF-07817883

  • Experimental
    PF-07817883 Dose 5 in PART-1

    Optional dose levels

    Drug: PF-07817883

  • Experimental
    PF-07817883 Dose 6 in PART-1

    Optional dose levels

    Drug: PF-07817883

  • Placebo comparator
    Placebo in PART-1

    A single dose of placebo

    Drug: Placebo

  • Experimental
    PF-07817883 DR1 in PART-2

    DR=Dosing regimen; twice a day

    Drug: PF-07817883

  • Experimental
    PF-07817883 DR2 in PART-2

    Drug: PF-07817883

  • Experimental
    PF-07817883 DR3 in PART-2

    Optional dosing regimen

    Drug: PF-07817883

  • Experimental
    PF-07817883 DR4 in PART-2

    Optional dosing regimen

    Drug: PF-07817883

  • Experimental
    PF-07817883 in Japanese in PART-2

    Optional dosing regimen to be studied in Japanese population

    Drug: PF-07817883

  • Experimental
    PF-07817883 in Chinese in PART-2

    Optional dosing regimen to be studied in Chinese population

    Drug: PF-07817883

  • Placebo comparator
    Placebo in PART-2

    Drug: Placebo

  • Experimental
    PF-07817883 Suspension Fasted in PART-3

    PART-3 is optional

    Drug: PF-07817883

  • Experimental
    PF-07817883 FORM-1 Fasted in PART-3

    First solid oral formulation (FORM1)

    Drug: PF-07817883

  • Experimental
    PF-07817883 FORM-2 Fasted in PART-3

    Second solid oral formulations (FORM-2) is optional

    Drug: PF-07817883

  • Experimental
    PF-07817883 FORM-1 Fed in PART-3

    Drug: PF-07817883

  • Experimental
    PF-07817883 FORM-2 Fed in PART-3

    Drug: PF-07817883

  • Experimental
    PF-07817883 in PART-4

    PART-4 is optional

    Drug: PF-07817883

  • Experimental
    Midazolam 5 mg in PART-5

    Single dose of 5 mg alone

    Drug: Midazolam

  • Experimental
    Midazolam 5 mg with PF-07817883 in PART-5

    Single dose of 5 mg on Day 10 with multiple doses (twice a day) of PF-07817883

    Drug: PF-07817883 · Drug: Midazolam

  • Experimental
    PF-07817883 in PART-6

    A single dose at supratherapeutic exposure administered as divided doses (1h apart)

    Drug: PF-07817883

  • Placebo comparator
    Placebo in PART-6

    A single dose of placebo administered as divided doses (1h apart)

    Drug: Placebo

  • Active comparator
    Moxifloxacin 400 mg in PART-6 (open label)

    Moxifloxacin 400 mg at 0h followed by placebo at 1h

    Drug: Placebo · Drug: Moxifloxacin

Interventions

  • Oral suspension or solid oral formulation(s)

  • DrugPlacebo

    Placebo suspension

  • midazolam oral solution

  • Moxifloxacin 400 mg tablet

06

What researchers measure

Primary outcomes

  1. Part 1: Number of Participants With Treatment Emergent Adverse Events (TEAEs)

    An adverse event (AE) was any untoward medical occurrence in a participant temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE was considered a TEAE if the event started during the effective duration of treatment. All events that started on or after the first dosing day and time/start time, if collected, but before the end of the study were considered as TEAEs.

    Time frame: From start of study treatment up to 28-35 days after administration of last dose of study intervention (maximum up to 48 days)

  2. Part 1: Number of Participants With Laboratory Test Abnormalities

    Laboratory parameters included: (lymphocytes less than (\<) 0.8\*lower limit of normal \[LLN\] \[10\^3 per millimeter cube {mm3}\], lymphocytes/leukocytes \<0.8\*LLN \[percentage {%}\], neutrophils \<0.8\*LLN \[10\^3/mm3\], neutrophils/leukocytes \<0.8\*LLN \[%\], monocytes/leukocytes greater than (\>) 1.2\*upper limit of normal \[ULN\] \[%\], partial thromboplastin time \>1.1\*ULN \[seconds\]), chemistry (bicarbonate \<0.9\*LLN \[milliequivalents per liter {mEq/L}\], creatine kinase \>2.0\*ULN \[units per liter {U/L}\], lipase \>1.5\*ULN \[U/L\]), and urinalysis (urine hemoglobin greater than or equal to \[\>=\] 1, leukocyte esterase \>=1). Number of participants with any lab test abnormalities meeting the pre-specified criteria are reported in this outcome measure.

    Time frame: From start of study treatment up to 28-35 days after administration of last dose of study intervention (maximum up to 48 days)

  3. Part 1: Number of Participants With Vital Signs Meeting Pre-Defined Criteria

    Vital signs including systolic blood pressure (SBP), diastolic blood pressure (DBP) and pulse rate (PR) were measured in a supine position after approximately 5 minutes of rest for the participant. Criteria for vital signs included: SBP: value less than (\<) 90 millimeter of mercury (mmHg), change greater than or equal to (\>=) 30 mmHg increase, change \>= 30 mmHg decrease; DBP: value \< 50 mmHg, change \>= 20 mmHg increase, change \>= 20 mmHg decrease; PR: value \< 40 beats per minute (bpm), value \> 120 bpm.

    Time frame: Up to Day 2 of each period

  4. Part 1: Number of Participants With Electrocardiogram (ECG) Abnormalities

    Standard 12 lead ECGs were obtained with the participant in a supine position after at least 5 minutes of rest using an ECG machine that automatically calculated the heart rate and measured PR interval, QT interval, QTcF and QRS complex. Number of participants with abnormalities in ECG were reported in this outcome measure.

    Time frame: Up to Day 2 of each period

  5. Part 2: Number of Participants With Treatment Emergent Adverse Events (TEAEs)

    An AE was any untoward medical occurrence in a participant temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE was considered a TEAE if the event started during the effective duration of treatment. All events that started on or after the first dosing day and time/start time, if collected, but before the end of the study were considered as TEAEs.

    Time frame: From start of study treatment up to 38-45 days after administration of last dose of study intervention (maximum up to 55 days)

  6. Part 2: Number of Participants With Laboratory Test Abnormalities

    Laboratory parameters included: hematology (lymphocytes/leukocytes \>1.2\*ULN \[%\], neutrophils \<0.8\*LLN \[10\^3/mm3\], neutrophils/leukocytes \<0.8\*LLN \[%\], monocytes/leukocytes \>1.2\*ULN \[%\]), chemistry (urate \>1.2\*ULN \[milligrams per deciliter\] {mg/dL}), and urinalysis (ketones \>=1, urine hemoglobin \>=1). Number of participants with any lab test abnormalities meeting the pre-specified criteria are reported in this outcome measure.

    Time frame: From start of study treatment up to 38-45 days after administration of last dose of study intervention (maximum up to 55 days)

  7. Part 2: Number of Participants With Vital Signs Meeting Pre-Defined Criteria

    Vital signs including SBP, DBP and PR were measured in a supine position after approximately 5 minutes of rest for the participant. Criteria for vital signs included: SBP: value \< 90 mmHg, change \>= 30 mmHg increase, change \>= 30 mmHg decrease; DBP: value \< 50 mmHg, change \>= 20 mmHg increase, change \>= 20 mmHg decrease; PR: value \< 40 bpm, value \> 120 bpm. 4. Number of participants with vital signs meeting any of the pre-defined criteria is reported in this outcome measure.

    Time frame: Up to Day 12

  8. Part 2: Number of Participants With Electrocardiogram (ECG) Abnormalities

    Standard 12 lead ECGs were obtained with the participant in a supine position after at least 5 minutes of rest using an ECG machine that automatically calculated the heart rate and measured PR interval, QT interval, QTcF and QRS complex. Number of participants with abnormalities in ECG were reported in this outcome measure.

    Time frame: Up to Day 12

  9. Part 3:Ratio Based on Area Under Plasma Concentration Time Curve From Time 0 to Time of Last Quantifiable Concentration (AUClast) and Area Under Concentration-Time Curve From Time 0 Extrapolated to Infinite Time (AUCinf) of Oral Formulation and Suspension

    Data for AUClast and AUCinf are reported in the descriptive section. AUClast was calculated by the linear/log trapezoidal method. AUCinf was calculated as AUClast + (Clast/kel), where Clast was the predicted plasma concentration at the last quantifiable time point from the log-linear regression analysis. Ratio based on AUClast and AUCinf of oral formulation and suspension were reported in statistical analysis.

    Time frame: Day 1 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48 hours post-dose)

  10. Part 3: Ratio Based on Maximum Observed Concentration (Cmax) of Oral Formulation and Suspension

    Data for Cmax are reported in the descriptive section. Ratio based on Cmax of oral formulation and suspension were reported in statistical analysis.

    Time frame: Day 1 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48 hours post-dose)

  11. Part 4: Percentage of Total Dose Administered Recovered in Urine

    The percentage of total dose administered recovered in urine was reported in this outcome measure.

    Time frame: Up to 144 hours post-dose

  12. Part 4: Percentage of Total Dose Administered Recovered in Feces

    The percentage of total dose administered recovered in feces was reported in this outcome measure.

    Time frame: Up to 144 hours post-dose

  13. Part 4: Percentage of Total Dose Administered Recovered in Urine and Feces

    The percentage of total dose administered recovered in urine and feces was reported in this outcome measure.

    Time frame: Up to 144 hours post-dose

  14. Part 5: Maximum Observed Concentration (Cmax) of Midazolam

    Cmax of midazolam was reported in this outcome measure.

    Time frame: Day 1 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 36, 48 hours post-dose) for Midazolam 5 mg arm and Day 10 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 36, 48 hours post-dose) for PF-07817883 600 mg (Suspension) BID/ Midazolam 5 mg arm

  15. Part 5: Area Under the Concentration -Time Curve From Time Zero (0) Extrapolated to Infinite Time (AUCinf) of Midazolam

    AUCinf of midazolam was reported in this outcome measure. AUCinf was calculated as AUClast + (Clast/kel), where Clast was the predicted plasma concentration at the last quantifiable time point from the log-linear regression analysis.

    Time frame: Day 1 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 36, 48 hours post-dose) for Midazolam 5 mg arm and Day 10 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 36, 48 hours post-dose) for PF-07817883 600 mg (Suspension) BID/ Midazolam 5 mg arm

  16. Part 6: Number of Participants With TEAEs

    An AE was any untoward medical occurrence in a participant temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE was considered a TEAE if the event started during the effective duration of treatment. All events that started on or after the first dosing day and time/start time, if collected, but before the end of the study were considered as TEAEs.

    Time frame: From start of study treatment up to 28-35 days after administration of last dose of study intervention (maximum up to 52 days)

  17. Part 6: Number of Participants With Laboratory Test Abnormalities

    Laboratory parameters included: hematology (lymphocytes \<0.6\*LLN \[10\^3/mm3\], lymphocytes/leukocytes \>1.2\*ULN \[%\], neutrophils \<0.8\*LLN \[10\^3/mm3\], neutrophils/leukocytes \<0.8\*LLN \[%\], basophils/leukocytes \>1.2\*ULN \[%\], eosinophils/leukocytes \>1.2\*ULN \[%\], monocytes/leukocytes \>1.2\*ULN \[%\], partial thromboplastin time \>1.1\*ULN \[seconds\], prothrombin time \>1.1\*ULN \[seconds\]), chemistry (bicarbonate \<0.9\*LLN \[mEq/L\], creatine kinase \> 2.0\*ULN \[U/L\], lipase \> 1.5\*ULN \[U/L\], urobilinogen \>=1 \[ehrlich units/deciliter\] {EU/dL}) and urinalysis (urine hemoglobin \>=1, leukocyte esterase \>=1, ketones \>=1, bacteria \>20 \[per low power field\] {/lpf}). Number of participants with any lab test abnormalities meeting the pre-specified criteria are reported in this outcome measure.

    Time frame: From start of study treatment up to 28-35 days after administration of last dose of study intervention (maximum up to 52 days)

  18. Part 6: Number of Participants With Vital Signs Meeting Pre-Defined Criteria

    Vital signs including SBP, DBP and PR were measured in a supine position after approximately 5 minutes of rest for the participant. Criteria for vital signs included: SBP: value \< 90 mmHg, change \>= 30 mmHg increase, change \>= 30 mmHg decrease; DBP: value \< 50 mmHg, change \>= 20 mmHg increase, change \>= 20 mmHg decrease; PR: value \< 40 bpm, value \> 120 bpm.

    Time frame: Up to Day 6 of each period

  19. Part 6: Number of Participants According to Categorization of ECG Data

    Standard 12 lead ECGs were obtained with the participant in a supine position after at least 5 minutes of rest using an ECG machine that automatically calculated the heart rate and measured QTcF interval, aggregate 450 milliseconds (msec) \< value \<= 480 msec and QTcF interval, aggregate 30 msec \< change \<= 60 msec. Number of participants with abnormalities in ECG were reported in this outcome measure.

    Time frame: Up to Day 6 of each period

Secondary outcomes

  1. Part 1: Maximum Observed Concentration (Cmax) of PF-07817883

    Cmax of PF-07817883 was reported in this outcome measure.

    Time frame: Day 1 (pre-dose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48, 72 hours post-dose)

  2. Part 1: Time for Cmax (Tmax) of PF-07817883

    Tmax of PF-07817883 was reported in this outcome measure.

    Time frame: Day 1 (pre-dose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48, 72 hours post-dose)

  3. Part 1: Area Under Plasma Concentration Time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of PF-07817883

    AUClast of PF-07817883 was reported in this outcome measure. AUClast was calculated by the linear/log trapezoidal method.

    Time frame: Day 1 (pre-dose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48, 72 hours post-dose)

  4. Part 1: Dose Normalized Cmax (Cmax[dn]) of PF-07817883

    Cmax(dn) of PF-07817883 was reported in this outcome measure. Cmax(dn) was calculated as Cmax/dose.

    Time frame: Day 1 (pre-dose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48, 72 hours post-dose)

  5. Part 1: Dose Normalized AUClast (AUClast[dn]) of PF-07817883

    AUClast(dn) of PF-07817883 was reported in this outcome measure. AUClast(dn) was calculated by AUClast/dose.

    Time frame: Day 1 (pre-dose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48, 72 hours post-dose)

  6. Part 1: Area Under the Concentration -Time Curve From Time Zero (0) Extrapolated to Infinite Time (AUCinf) of PF-07817883

    AUCinf of PF-07817883 was reported in this outcome measure. AUCinf was calculated as AUClast + (Clast/kel), where Clast was the predicted plasma concentration at the last quantifiable time point from the log-linear regression analysis.

    Time frame: Day 1 (pre-dose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48, 72 hours post-dose)

  7. Part 1: Dose Normalized AUCinf (AUCinf[dn]) of PF-07817883

    AUCinf(dn) of PF-07817883 was reported in this outcome measure. AUCinf(dn) was calculated as AUCinf/dose.

    Time frame: Day 1 (pre-dose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48, 72 hours post-dose)

  8. Part 1: Terminal Half-Life (t1/2) of PF-07817883

    t1/2 of PF-07817883 was reported in this outcome measure. t1/2 was calculated by Loge(2)/kel, where kel was the terminal phase rate constant calculated by a linear regression of the log linear concentration-time curve. Only those data points judged to describe the terminal log-linear decline were used in the regression.

    Time frame: Day 1 (pre-dose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48, 72 hours post-dose)

  9. Part 1: Apparent Volume of Distribution (Vz/F) of PF-07817883

    Vz/F of PF-07817883 was reported in this outcome measure. Vz/F was calculated as dose/(AUCinf\*kel).

    Time frame: Day 1 (pre-dose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48, 72 hours post-dose)

  10. Part 1: Apparent Clearance (CL/F) of PF-07817883

    CL/F of PF-07817883 was reported in this outcome measure. CL/F was calculated as dose/AUCinf.

    Time frame: Day 1 (pre-dose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48, 72 hours post-dose)

  11. Part 2: Maximum Observed Concentration (Cmax) of PF-07817883 on Days 1, 5 and 10

    Cmax of PF-07817883 was reported in this outcome measure.

    Time frame: Day 1 and Day 5 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12 hours post-dose) and Day 10 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48 hours post-dose)

  12. Part 2: Time for Cmax (Tmax) of PF-07817883 on Days 1, 5 and 10

    Tmax of PF-07817883 was reported in this outcome measure.

    Time frame: Day 1 and Day 5 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12 hours post-dose) and Day 10 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48 hours post-dose)

  13. Part 2: Area Under the Plasma Concentration-Time Profile From Time 0 to Time Tau, the Dosing Interval (AUCtau) of PF-07817883 on Days 1, 5 and 10

    AUCtau was defined as area under the plasma concentration-time profile from time 0 to time tau, the dosing interval, where tau= 12 hours. AUCtau of PF-07817883 was reported in this outcome measure. AUCtau was calculated by linear/log trapezoidal method.

    Time frame: Day 1 and Day 5 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12 hours post-dose) and Day 10 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12 hours post-dose)

  14. Part 2: Concentration at 12 Hour Nominal Time Post-Dose (C12) of PF-07817883 on Days 5 and 10

    C12 of PF-07817883 was reported in this outcome measure.

    Time frame: 12 hours on Day 5 and Day 10

  15. Part 2: Dose Normalized Cmax (Cmax[dn]) of PF-07817883 on Days 1, 5 and 10

    Cmax(dn) of PF-07817883 was reported in this outcome measure. Cmax(dn) was calculated as Cmax/dose.

    Time frame: Day 1 and Day 5 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12 hours post-dose) and Day 10 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48 hours post-dose)

  16. Part 2: Dose Normalized AUCtau (AUCtau[dn]) of PF-07817883 on Days 1, 5 and 10

    AUCtau(dn) was defined as dose normalized AUCtau, where tau= 12 hours. AUCtau(dn) of PF-07817883 was reported in this outcome measure. AUCtau(dn) was calculated as AUCtau/dose.

    Time frame: Day 1 and Day 5 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12 hours post-dose) and Day 10 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12 hours post-dose)

  17. Part 2: Average Concentration (Cav) of PF-07817883 on Days 5 and 10

    Cav of PF-07817883 was reported in this outcome measure. Cav was calculated as AUCtau/12.

    Time frame: Day 5 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12 hours post-dose) and Day 10 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12 hours post-dose)

  18. Part 2: Observed Accumulation Ratio for AUCtau (Rac) of PF-07817883 on Days 5 and 10

    Rac was defined as observed accumulation ratio for AUCtau, where tau= 12 hours. Rac of PF-07817883 was reported in this outcome measure. Rac was calculated as AUCtau on Day 5 or Day 10/AUCtau on Day 1.

    Time frame: Day 5 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12 hours post-dose) and Day 10 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12 hours post-dose)

  19. Part 2: Observed Accumulation Ratio for Cmax (Rac,Cmax) of PF-07817883 on Days 5 and 10

    Rac,Cmax of PF-07817883 was reported in this outcome measure. Rac,Cmax was calculated as Cmax on Day 5 or Day 10/Cmax on Day 1.

    Time frame: Day 5 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12 hours post-dose) and Day 10 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48 hours post-dose)

  20. Part 2: Peak-to-Trough Ratio (PTR) of PF-07817883 on Days 5 and 10

    PTR of PF-07817883 was reported in this outcome measure. PTR was calculated as Cmax/Cmin.

    Time frame: Day 5 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12 hours post-dose) and Day 10 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48 hours post-dose)

  21. Part 2: Apparent Clearance (CL/F) of PF-07817883 on Days 5 and 10

    CL/F of PF-07817883 was reported in this outcome measure. CL/F was calculated as dose/AUCinf.

    Time frame: Day 5 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12 hours post-dose) and Day 10 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48 hours post-dose)

  22. Part 2: Apparent Volume of Distribution (Vz/F) of PF-07817883 on Day 10

    Vz/F of PF-07817883 was reported in this outcome measure. Vz/F was calculated as dose/(AUCtau\*kel).

    Time frame: Day 10 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48 hours post-dose)

  23. Part 2: Terminal Half-Life (t1/2) of PF-07817883 on Day 10

    t1/2 of PF-07817883 was reported in this outcome measure. t1/2 was calculated by Loge(2)/kel, where kel was the terminal phase rate constant calculated by a linear regression of the log linear concentration-time curve. Only those data points judged to describe the terminal log-linear decline were used in the regression.

    Time frame: Day 10 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48 hours post-dose)

  24. Part 2: Amount Excreted in Urine as Unchanged Drug Over the Dosing Interval Tau (Aetau) of PF-07817883 on Day 10

    Aetau was defined as amount excreted in urine as unchanged drug over the dosing interval tau, where tau= 12 hours. Aetau of PF-07817883 was reported in this outcome measure. Aetau was calculated as sum of (urine volume\*urine concentration) for each collection over the dosing interval.

    Time frame: Day 10 (0 to 12 hours)

  25. Part 2: Percent of Dose Excreted in Urine as Unchanged Drug Over the Dosing Interval Tau (Aetau%) of PF-07817883 on Day 10

    Aetau% was defined as percentage of dose excreted in urine as unchanged drug over the dosing interval tau, where tau= 12 hours. Aetau% of PF-07817883 was reported in this outcome measure. Aetau% was calculated as 100\*Aetau/dose.

    Time frame: Day 10 (0 to 12 hours)

  26. Part 2: Renal Clearance (CLr) of PF-07817883 on Day 10

    CLr of PF-07817883 was reported in this outcome measure. CLr was calculated as Aetau/AUCtau.

    Time frame: Day 10 (0 to 12 hours)

  27. Part 3: Ratio Based on AUClast and AUCinf of Tablet Formulation Under Fed Condition and Fasted Condition

    Data for AUClast and AUCinf are reported in the descriptive section. AUClast was calculated by the linear/log trapezoidal method. AUCinf was calculated as AUClast + (Clast/kel), where Clast was the predicted plasma concentration at the last quantifiable time point from the log-linear regression analysis. Ratio based on AUClast and AUCinf of tablet formulations under fed and fasted conditions were reported in statistical analysis.

    Time frame: Day 1 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48 hours post-dose)

  28. Part 3: Ratio Based on Maximum Observed Concentration (Cmax) of Tablet Formulation Under Fed Condition and Fasted Condition

    Data for Cmax are reported in the descriptive section. Ratio based on Cmax of tablet formulation under fed and fasted conditions were reported in statistical analysis.

    Time frame: Day 1 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48 hours post-dose)

  29. Part 3: Time for Cmax (Tmax) of PF-07817883

    Tmax of PF-07817883 was reported in this outcome measure.

    Time frame: Day 1 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48 hours post-dose)

  30. Part 3: Maximum Observed Concentration (Cmax) of PF-07817883

    Cmax of PF-07817883 was reported in this outcome measure.

    Time frame: Day 1 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48 hours post-dose)

  31. Part 3: Area Under Plasma Concentration Time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of PF-07817883

    AUClast of PF-07817883 was reported in this outcome measure. AUClast was calculated by the linear/log trapezoidal method.

    Time frame: Day 1 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48 hours post-dose)

  32. Part 3: Area Under the Concentration -Time Curve From Time Zero (0) Extrapolated to Infinite Time (AUCinf) of PF-07817883

    AUCinf of PF-07817883 was reported in this outcome measure. AUCinf was calculated as AUClast + (Clast/kel), where Clast was the predicted plasma concentration at the last quantifiable time point from the log-linear regression analysis.

    Time frame: Day 1 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48 hours post-dose)

  33. Part 3: Terminal Half-Life (t1/2) of PF-07817883

    t1/2 of PF-07817883 was reported in this outcome measure. t1/2 was calculated by Loge(2)/kel, where kel was the terminal phase rate constant calculated by a linear regression of the log linear concentration-time curve. Only those data points judged to describe the terminal log-linear decline were used in the regression.

    Time frame: Day 1 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48 hours post-dose)

  34. Part 3: Apparent Clearance (CL/F) of PF-07817883

    CL/F of PF-07817883 was reported in this outcome measure. CL/F was calculated as dose/AUCinf.

    Time frame: Day 1 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48 hours post-dose)

  35. Part 3: Apparent Volume of Distribution (Vz/F) of PF-07817883

    Vz/F of PF-07817883 was reported in this outcome measure. Vz/F was calculated as dose/(AUCtau\*kel).

    Time frame: Day 1 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48 hours post-dose)

  36. Part 3: Number of Participants With TEAEs

    An AE was any untoward medical occurrence in a participant temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE was considered a TEAE if the event started during the effective duration of treatment. All events that started on or after the first dosing day and time/start time, if collected, but before the end of the study were considered as TEAEs.

    Time frame: From start of study treatment up to 29-36 days after administration of last dose of study intervention (maximum up to 49 days)

  37. Part 3: Number of Participants With Laboratory Test Abnormalities

    Laboratory parameters included: hematology (monocytes/leukocytes \>1.2\*ULN \[%\], partial thromboplastin time \>1.1\*ULN \[seconds\]) and urinalysis (urine hemoglobin \>=1, bacteria \>20 \[/lpf\]). Number of participants with any lab test abnormalities meeting the pre-specified criteria are reported in this outcome measure.

    Time frame: From start of study treatment up to 29-36 days after administration of last dose of study intervention (maximum up to 49 days)

  38. Part 3: Number of Participants With Vital Signs Meeting Pre-Defined Criteria

    Vital signs including SBP, DBP and PR were measured in a supine position after approximately 5 minutes of rest for the participant. Criteria for vital signs included: SBP: value \< 90 mmHg, change \>= 30 mmHg increase, change \>= 30 mmHg decrease; DBP: value \< 50 mmHg, change \>= 20 mmHg increase, change \>= 20 mmHg decrease; PR: value \< 40 bpm, value \> 120 bpm. 4. Number of participants with vital signs meeting any of the pre-defined criteria is reported in this outcome measure.

    Time frame: Up to Day 3 of each period

  39. Part 3: Number of Participants With ECG Abnormalities

    Standard 12 lead ECGs were obtained with the participant in a supine position after at least 5 minutes of rest using an ECG machine that automatically calculated the heart rate and measured PR interval, QT interval, QTcF and QRS complex. Number of participants with abnormalities in ECG were reported in this outcome measure.

    Time frame: Up to Day 3 of each period

  40. Part 4: Time for Cmax (Tmax) of PF-07817883

    Tmax of PF-07817883 was reported in this outcome measure.

    Time frame: Day 1 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48, 72 hours post-dose)

  41. Part 4: Maximum Observed Concentration (Cmax) of PF-07817883

    Cmax of PF-07817883 was reported in this outcome measure.

    Time frame: Day 1 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48, 72 hours post-dose)

  42. Part 4: Area Under Plasma Concentration Time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of PF-07817883

    AUClast of PF-07817883 was reported in this outcome measure. AUClast was calculated by the linear/log trapezoidal method.

    Time frame: Day 1 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48, 72 hours post-dose)

  43. Part 4: Area Under the Concentration -Time Curve From Time Zero (0) Extrapolated to Infinite Time (AUCinf) of PF-07817883

    AUCinf of PF-07817883 was reported in this outcome measure. AUCinf was calculated as AUClast + (Clast/kel), where Clast was the predicted plasma concentration at the last quantifiable time point from the log-linear regression analysis.

    Time frame: Day 1 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48, 72 hours post-dose)

  44. Part 4: Terminal Half-Life (t1/2) of PF-07817883

    t1/2 of PF-07817883 was reported in this outcome measure. t1/2 was calculated by Loge(2)/kel, where kel was the terminal phase rate constant calculated by a linear regression of the log linear concentration-time curve. Only those data points judged to describe the terminal log-linear decline were used in the regression.

    Time frame: Day 1 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48, 72 hours post-dose)

  45. Part 4: Apparent Clearance (CL/F) of PF-07817883

    CL/F of PF-07817883 was reported in this outcome measure. CL/F was calculated as dose/AUCinf.

    Time frame: Day 1 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48, 72 hours post-dose)

  46. Part 4: Apparent Volume of Distribution (Vz/F) of PF-07817883

    Vz/F of PF-07817883 was reported in this outcome measure. Vz/F was calculated as dose/(AUCtau\*kel).

    Time frame: Day 1 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48, 72 hours post-dose)

  47. Part 4: Number of Participants With TEAEs

    An AE was any untoward medical occurrence in a participant temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE was considered a TEAE if the event started during the effective duration of treatment. All events that started on or after the first dosing day and time/start time, if collected, but before the end of the study were considered as TEAEs.

    Time frame: From start of study treatment up to 29-36 days after administration of last dose of study intervention (maximum up to 47 days)

  48. Part 4: Number of Participants With Laboratory Test Abnormalities

    Laboratory parameters included: hematology (mean corpuscular volume \<0.9\*LLN \[cubic micrometer {um\^3}\], mean corpuscular hemoglobin \<0.9\*LLN \[picograms per cell {pg/cell}\], monocytes/leukocytes \>1.2\*ULN \[%\]). Number of participants with any lab test abnormalities meeting the pre-specified criteria are reported in this outcome measure.

    Time frame: From start of study treatment up to 29-36 days after administration of last dose of study intervention (maximum up to 47 days)

  49. Part 4: Number of Participants With Vital Signs Meeting Pre-Defined Criteria

    Vital signs including SBP, DBP and PR were measured in a supine position after approximately 5 minutes of rest for the participant. Criteria for vital signs included: SBP: value \< 90 mmHg, change \>= 30 mmHg increase, change \>= 30 mmHg decrease; DBP: value \< 50 mmHg, change \>= 20 mmHg increase, change \>= 20 mmHg decrease; PR: value \< 40 bpm, value \> 120 bpm.

    Time frame: Up to Day 11

  50. Part 4: Number of Participants With ECG Abnormalities

    Standard 12 lead ECGs were obtained with the participant in a supine position after at least 5 minutes of rest using an ECG machine that automatically calculated the heart rate and measured PR interval, QT interval, QTcF and QRS complex. Number of participants with abnormalities in ECG were reported in this outcome measure.

    Time frame: Up to Day 11

  51. Part 5: Number of Participants With TEAEs

    An AE was any untoward medical occurrence in a participant temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE was considered a TEAE if the event started during the effective duration of treatment. All events that started on or after the first dosing day and time/start time, if collected, but before the end of the study were considered as TEAEs.

    Time frame: From start of study treatment up to 38-45 days after administration of last dose of study intervention (maximum up to 65 days)

  52. Part 5: Number of Participants With Laboratory Test Abnormalities

    Laboratory parameters included: hematology (lymphocytes \<0.8\*LLN \[10\^3/mm3\], lymphocytes/leukocytes \<0.8\*LLN \[%\], neutrophils/leukocytes \<0.8\*LLN \[%\], monocytes/leukocytes \>1.2\*ULN \[%\]), chemistry (amylase \>1.5\*ULN \[units/liter\] {U/L}), and urinalysis (urine hemoglobin \>=1). Number of participants with any lab test abnormalities meeting the pre-specified criteria are reported in this outcome measure.

    Time frame: From start of study treatment up to 38-45 days after administration of last dose of study intervention (maximum up to 65 days)

  53. Part 5: Number of Participants With Vital Signs Meeting Pre-Defined Criteria

    Vital signs including SBP, DBP and PR were measured in a supine position after approximately 5 minutes of rest for the participant. Criteria for vital signs included: SBP: value \< 90 mmHg, change \>= 30 mmHg increase, change \>= 30 mmHg decrease; DBP: value \< 50 mmHg, change \>= 20 mmHg increase, change \>= 20 mmHg decrease; PR: value \< 40 bpm, value \> 120 bpm.

    Time frame: From start of study treatment up to 38-45 days after administration of last dose of study intervention (maximum up to 65 days)

  54. Part 5: Number of Participants With ECG Abnormalities

    Standard 12 lead ECGs were obtained with the participant in a supine position after at least 5 minutes of rest using an ECG machine that automatically calculated the heart rate and measured PR interval, QT interval, QTcF and QRS complex. Number of participants with abnormalities in ECG were reported in this outcome measure.

    Time frame: From start of study treatment up to 38-45 days after administration of last dose of study intervention (maximum up to 65 days)

  55. Part 5: Time for Cmax (Tmax) of Midazolam

    Tmax of midazolam was reported in this outcome measure.

    Time frame: Day 1 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 36, 48 hours post-dose) for Midazolam 5 mg arm and Day 10 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 36, 48 hours post-dose) for PF-07817883 600 mg (Suspension) BID/ Midazolam 5 mg arm

  56. Part 5: Area Under Plasma Concentration Time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of Midazolam

    AUClast of midazolam was reported in this outcome measure. AUClast was calculated by the linear/log trapezoidal method.

    Time frame: Day 1 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 36, 48 hours post-dose) for Midazolam 5 mg arm and Day 10 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 36, 48 hours post-dose) for PF-07817883 600 mg (Suspension) BID/ Midazolam 5 mg arm

  57. Part 5: Terminal Half-Life (t1/2) of Midazolam

    t1/2 of midazolam was reported in this outcome measure. t1/2 was calculated by Loge(2)/kel, where kel was the terminal phase rate constant calculated by a linear regression of the log linear concentration-time curve. Only those data points judged to describe the terminal log-linear decline were used in the regression.

    Time frame: Day 1 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 36, 48 hours post-dose) for Midazolam 5 mg arm and Day 10 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 36, 48 hours post-dose) for PF-07817883 600 mg (Suspension) BID/ Midazolam 5 mg arm

  58. Part 5: Apparent Clearance (CL/F) of Midazolam

    CL/F of midazolam was reported in this outcome measure. CL/F was calculated as dose/AUCinf.

    Time frame: Day 1 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 36, 48 hours post-dose) for Midazolam 5 mg arm and Day 10 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 36, 48 hours post-dose) for PF-07817883 600 mg (Suspension) BID/ Midazolam 5 mg arm

  59. Part 5: Apparent Volume of Distribution (Vz/F) of Midazolam

    Vz/F of midazolam was reported in this outcome measure. Vz/F was calculated as dose/(AUCinf\*kel).

    Time frame: Day 1 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 36, 48 hours post-dose) for Midazolam 5 mg arm and Day 10 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 36, 48 hours post-dose) for PF-07817883 600 mg (Suspension) BID/ Midazolam 5 mg arm

  60. Part 6: Maximum Observed Concentration (Cmax) of PF-07817883

    Cmax of PF-07817883 was reported in this outcome measure.

    Time frame: Day 1 (pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours post-dose)

  61. Part 6: Time for Cmax (Tmax) of PF-07817883

    Tmax of PF-07817883 was reported in this outcome measure.

    Time frame: Day 1 (pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours post-dose)

  62. Part 6: Area Under Plasma Concentration Time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of PF-07817883

    AUClast of PF-07817883 was reported in this outcome measure. AUClast was calculated by the linear/log trapezoidal method.

    Time frame: Day 1 (pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours post-dose)

  63. Part 6: Area Under the Concentration -Time Curve From Time Zero (0) Extrapolated to Infinite Time (AUCinf) of PF-07817883

    AUCinf of PF-07817883 was reported in this outcome measure. AUCinf was calculated as AUClast + (Clast/kel), where Clast was the predicted plasma concentration at the last quantifiable time point from the log-linear regression analysis.

    Time frame: Day 1 (pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours post-dose)

  64. Part 6: Terminal Half-Life (t1/2) of PF-07817883

    t1/2 of PF-07817883 was reported in this outcome measure. t1/2 was calculated by Loge(2)/kel, where kel was the terminal phase rate constant calculated by a linear regression of the log linear concentration-time curve. Only those data points judged to describe the terminal log-linear decline were used in the regression.

    Time frame: Day 1 (pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours post-dose)

07

Results

Posted Nov 21, 2024

Participant flow

Part (P) 1 Treatment Period 1 (Day 1)
Participant flow — Part (P) 1 Treatment Period 1 (Day 1)
MilestoneP1: C1: Placebo,Fast/PF-07817883 1500mg,Fast/PF-07817883 4000mg, FastP1: C1: PF-07817883 150mg,Fast/Placebo,Fast/PF-07817883 4000mg,FastP1: C1: PF-07817883 150 mg,Fast/PF-07817883 1500mg,Fast/Placebo,FastP1: C1: PF-07817883 150 mg,Fast/PF-07817883 1500mg,Fast/PF-07817883 4000mg,FastP1: C2: Placebo,Fast/PF-07817883 3000mg,Fast/Placebo,FedP1: C2: PF-07817883 500mg,Fast/Placebo,Fast/PF-07817883 500mg,FedP1: C2: PF-07817883 500mg,Fast/PF-07817883 3000mg,Fast/PF-07817883 500mg,FedPart 2: Placebo (Suspension) BID, FastedPart 2: PF-07817883 200 mg (Suspension) BID, FastedPart 2: PF-07817883 600 mg (Suspension) BID, FastedPart 2: PF-07817883 1500 mg (Suspension) BID, FastedPart 2: Placebo (Suspension) BID, Fasted, ChinesePart 2: PF-07817883 600 mg (Suspension) BID, Fasted, ChinesePart 3: Treatment Sequence ABCDPart 3: Treatment Sequence BCADPart 3: Treatment Sequence CABDPart 3: Treatment Sequence BACEPart 3: Treatment Sequence ACBEPart 3: Treatment Sequence CBAEPart 4: PF-07817883 600 mg (Suspension), FastedPart 5: Treatment Sequence ABPart 5: Treatment Sequence BAPart 6: Treatment Sequence ABCPart 6: Treatment Sequence BCAPart 6: Treatment Sequence CABPart 6: Treatment Sequence BACPart 6: Treatment Sequence ACBPart 6: Treatment Sequence CBA
Started2222224000000000000000000000
Completed2222223000000000000000000000
Not completed0000001000000000000000000000
Withdrew: Withdrawal by subject0000001000000000000000000000
Part 1: Washout 1 (up to 5 Days)
Participant flow — Part 1: Washout 1 (up to 5 Days)
MilestoneP1: C1: Placebo,Fast/PF-07817883 1500mg,Fast/PF-07817883 4000mg, FastP1: C1: PF-07817883 150mg,Fast/Placebo,Fast/PF-07817883 4000mg,FastP1: C1: PF-07817883 150 mg,Fast/PF-07817883 1500mg,Fast/Placebo,FastP1: C1: PF-07817883 150 mg,Fast/PF-07817883 1500mg,Fast/PF-07817883 4000mg,FastP1: C2: Placebo,Fast/PF-07817883 3000mg,Fast/Placebo,FedP1: C2: PF-07817883 500mg,Fast/Placebo,Fast/PF-07817883 500mg,FedP1: C2: PF-07817883 500mg,Fast/PF-07817883 3000mg,Fast/PF-07817883 500mg,FedPart 2: Placebo (Suspension) BID, FastedPart 2: PF-07817883 200 mg (Suspension) BID, FastedPart 2: PF-07817883 600 mg (Suspension) BID, FastedPart 2: PF-07817883 1500 mg (Suspension) BID, FastedPart 2: Placebo (Suspension) BID, Fasted, ChinesePart 2: PF-07817883 600 mg (Suspension) BID, Fasted, ChinesePart 3: Treatment Sequence ABCDPart 3: Treatment Sequence BCADPart 3: Treatment Sequence CABDPart 3: Treatment Sequence BACEPart 3: Treatment Sequence ACBEPart 3: Treatment Sequence CBAEPart 4: PF-07817883 600 mg (Suspension), FastedPart 5: Treatment Sequence ABPart 5: Treatment Sequence BAPart 6: Treatment Sequence ABCPart 6: Treatment Sequence BCAPart 6: Treatment Sequence CABPart 6: Treatment Sequence BACPart 6: Treatment Sequence ACBPart 6: Treatment Sequence CBA
Started2222223000000000000000000000
Completed2222223000000000000000000000
Not completed0000000000000000000000000000
Part 1 Treatment Period 2 (Day 1)
Participant flow — Part 1 Treatment Period 2 (Day 1)
MilestoneP1: C1: Placebo,Fast/PF-07817883 1500mg,Fast/PF-07817883 4000mg, FastP1: C1: PF-07817883 150mg,Fast/Placebo,Fast/PF-07817883 4000mg,FastP1: C1: PF-07817883 150 mg,Fast/PF-07817883 1500mg,Fast/Placebo,FastP1: C1: PF-07817883 150 mg,Fast/PF-07817883 1500mg,Fast/PF-07817883 4000mg,FastP1: C2: Placebo,Fast/PF-07817883 3000mg,Fast/Placebo,FedP1: C2: PF-07817883 500mg,Fast/Placebo,Fast/PF-07817883 500mg,FedP1: C2: PF-07817883 500mg,Fast/PF-07817883 3000mg,Fast/PF-07817883 500mg,FedPart 2: Placebo (Suspension) BID, FastedPart 2: PF-07817883 200 mg (Suspension) BID, FastedPart 2: PF-07817883 600 mg (Suspension) BID, FastedPart 2: PF-07817883 1500 mg (Suspension) BID, FastedPart 2: Placebo (Suspension) BID, Fasted, ChinesePart 2: PF-07817883 600 mg (Suspension) BID, Fasted, ChinesePart 3: Treatment Sequence ABCDPart 3: Treatment Sequence BCADPart 3: Treatment Sequence CABDPart 3: Treatment Sequence BACEPart 3: Treatment Sequence ACBEPart 3: Treatment Sequence CBAEPart 4: PF-07817883 600 mg (Suspension), FastedPart 5: Treatment Sequence ABPart 5: Treatment Sequence BAPart 6: Treatment Sequence ABCPart 6: Treatment Sequence BCAPart 6: Treatment Sequence CABPart 6: Treatment Sequence BACPart 6: Treatment Sequence ACBPart 6: Treatment Sequence CBA
Started2222223000000000000000000000
Completed2221213000000000000000000000
Not completed0001010000000000000000000000
Withdrew: Physician decision0000010000000000000000000000
Withdrew: Other0001000000000000000000000000
Part 1: Washout 2 (up to 5 Days)
Participant flow — Part 1: Washout 2 (up to 5 Days)
MilestoneP1: C1: Placebo,Fast/PF-07817883 1500mg,Fast/PF-07817883 4000mg, FastP1: C1: PF-07817883 150mg,Fast/Placebo,Fast/PF-07817883 4000mg,FastP1: C1: PF-07817883 150 mg,Fast/PF-07817883 1500mg,Fast/Placebo,FastP1: C1: PF-07817883 150 mg,Fast/PF-07817883 1500mg,Fast/PF-07817883 4000mg,FastP1: C2: Placebo,Fast/PF-07817883 3000mg,Fast/Placebo,FedP1: C2: PF-07817883 500mg,Fast/Placebo,Fast/PF-07817883 500mg,FedP1: C2: PF-07817883 500mg,Fast/PF-07817883 3000mg,Fast/PF-07817883 500mg,FedPart 2: Placebo (Suspension) BID, FastedPart 2: PF-07817883 200 mg (Suspension) BID, FastedPart 2: PF-07817883 600 mg (Suspension) BID, FastedPart 2: PF-07817883 1500 mg (Suspension) BID, FastedPart 2: Placebo (Suspension) BID, Fasted, ChinesePart 2: PF-07817883 600 mg (Suspension) BID, Fasted, ChinesePart 3: Treatment Sequence ABCDPart 3: Treatment Sequence BCADPart 3: Treatment Sequence CABDPart 3: Treatment Sequence BACEPart 3: Treatment Sequence ACBEPart 3: Treatment Sequence CBAEPart 4: PF-07817883 600 mg (Suspension), FastedPart 5: Treatment Sequence ABPart 5: Treatment Sequence BAPart 6: Treatment Sequence ABCPart 6: Treatment Sequence BCAPart 6: Treatment Sequence CABPart 6: Treatment Sequence BACPart 6: Treatment Sequence ACBPart 6: Treatment Sequence CBA
Started2221213000000000000000000000
Completed2221213000000000000000000000
Not completed0000000000000000000000000000
Part 1: Treatment Period 3 (Day 1)
Participant flow — Part 1: Treatment Period 3 (Day 1)
MilestoneP1: C1: Placebo,Fast/PF-07817883 1500mg,Fast/PF-07817883 4000mg, FastP1: C1: PF-07817883 150mg,Fast/Placebo,Fast/PF-07817883 4000mg,FastP1: C1: PF-07817883 150 mg,Fast/PF-07817883 1500mg,Fast/Placebo,FastP1: C1: PF-07817883 150 mg,Fast/PF-07817883 1500mg,Fast/PF-07817883 4000mg,FastP1: C2: Placebo,Fast/PF-07817883 3000mg,Fast/Placebo,FedP1: C2: PF-07817883 500mg,Fast/Placebo,Fast/PF-07817883 500mg,FedP1: C2: PF-07817883 500mg,Fast/PF-07817883 3000mg,Fast/PF-07817883 500mg,FedPart 2: Placebo (Suspension) BID, FastedPart 2: PF-07817883 200 mg (Suspension) BID, FastedPart 2: PF-07817883 600 mg (Suspension) BID, FastedPart 2: PF-07817883 1500 mg (Suspension) BID, FastedPart 2: Placebo (Suspension) BID, Fasted, ChinesePart 2: PF-07817883 600 mg (Suspension) BID, Fasted, ChinesePart 3: Treatment Sequence ABCDPart 3: Treatment Sequence BCADPart 3: Treatment Sequence CABDPart 3: Treatment Sequence BACEPart 3: Treatment Sequence ACBEPart 3: Treatment Sequence CBAEPart 4: PF-07817883 600 mg (Suspension), FastedPart 5: Treatment Sequence ABPart 5: Treatment Sequence BAPart 6: Treatment Sequence ABCPart 6: Treatment Sequence BCAPart 6: Treatment Sequence CABPart 6: Treatment Sequence BACPart 6: Treatment Sequence ACBPart 6: Treatment Sequence CBA
Started2221213000000000000000000000
Completed2121213000000000000000000000
Not completed0100000000000000000000000000
Withdrew: Physician decision0100000000000000000000000000
Part 2 (up to 10 Days)
Participant flow — Part 2 (up to 10 Days)
MilestoneP1: C1: Placebo,Fast/PF-07817883 1500mg,Fast/PF-07817883 4000mg, FastP1: C1: PF-07817883 150mg,Fast/Placebo,Fast/PF-07817883 4000mg,FastP1: C1: PF-07817883 150 mg,Fast/PF-07817883 1500mg,Fast/Placebo,FastP1: C1: PF-07817883 150 mg,Fast/PF-07817883 1500mg,Fast/PF-07817883 4000mg,FastP1: C2: Placebo,Fast/PF-07817883 3000mg,Fast/Placebo,FedP1: C2: PF-07817883 500mg,Fast/Placebo,Fast/PF-07817883 500mg,FedP1: C2: PF-07817883 500mg,Fast/PF-07817883 3000mg,Fast/PF-07817883 500mg,FedPart 2: Placebo (Suspension) BID, FastedPart 2: PF-07817883 200 mg (Suspension) BID, FastedPart 2: PF-07817883 600 mg (Suspension) BID, FastedPart 2: PF-07817883 1500 mg (Suspension) BID, FastedPart 2: Placebo (Suspension) BID, Fasted, ChinesePart 2: PF-07817883 600 mg (Suspension) BID, Fasted, ChinesePart 3: Treatment Sequence ABCDPart 3: Treatment Sequence BCADPart 3: Treatment Sequence CABDPart 3: Treatment Sequence BACEPart 3: Treatment Sequence ACBEPart 3: Treatment Sequence CBAEPart 4: PF-07817883 600 mg (Suspension), FastedPart 5: Treatment Sequence ABPart 5: Treatment Sequence BAPart 6: Treatment Sequence ABCPart 6: Treatment Sequence BCAPart 6: Treatment Sequence CABPart 6: Treatment Sequence BACPart 6: Treatment Sequence ACBPart 6: Treatment Sequence CBA
Started0000000644413000000000000000
Completed0000000643413000000000000000
Not completed0000000001000000000000000000
Withdrew: Other0000000001000000000000000000
Part 3 Period 1 (Day 1)
Participant flow — Part 3 Period 1 (Day 1)
MilestoneP1: C1: Placebo,Fast/PF-07817883 1500mg,Fast/PF-07817883 4000mg, FastP1: C1: PF-07817883 150mg,Fast/Placebo,Fast/PF-07817883 4000mg,FastP1: C1: PF-07817883 150 mg,Fast/PF-07817883 1500mg,Fast/Placebo,FastP1: C1: PF-07817883 150 mg,Fast/PF-07817883 1500mg,Fast/PF-07817883 4000mg,FastP1: C2: Placebo,Fast/PF-07817883 3000mg,Fast/Placebo,FedP1: C2: PF-07817883 500mg,Fast/Placebo,Fast/PF-07817883 500mg,FedP1: C2: PF-07817883 500mg,Fast/PF-07817883 3000mg,Fast/PF-07817883 500mg,FedPart 2: Placebo (Suspension) BID, FastedPart 2: PF-07817883 200 mg (Suspension) BID, FastedPart 2: PF-07817883 600 mg (Suspension) BID, FastedPart 2: PF-07817883 1500 mg (Suspension) BID, FastedPart 2: Placebo (Suspension) BID, Fasted, ChinesePart 2: PF-07817883 600 mg (Suspension) BID, Fasted, ChinesePart 3: Treatment Sequence ABCDPart 3: Treatment Sequence BCADPart 3: Treatment Sequence CABDPart 3: Treatment Sequence BACEPart 3: Treatment Sequence ACBEPart 3: Treatment Sequence CBAEPart 4: PF-07817883 600 mg (Suspension), FastedPart 5: Treatment Sequence ABPart 5: Treatment Sequence BAPart 6: Treatment Sequence ABCPart 6: Treatment Sequence BCAPart 6: Treatment Sequence CABPart 6: Treatment Sequence BACPart 6: Treatment Sequence ACBPart 6: Treatment Sequence CBA
Started0000000000000222222000000000
Completed0000000000000222222000000000
Not completed0000000000000000000000000000
Part 3: Washout 1 (up to 3 Days)
Participant flow — Part 3: Washout 1 (up to 3 Days)
MilestoneP1: C1: Placebo,Fast/PF-07817883 1500mg,Fast/PF-07817883 4000mg, FastP1: C1: PF-07817883 150mg,Fast/Placebo,Fast/PF-07817883 4000mg,FastP1: C1: PF-07817883 150 mg,Fast/PF-07817883 1500mg,Fast/Placebo,FastP1: C1: PF-07817883 150 mg,Fast/PF-07817883 1500mg,Fast/PF-07817883 4000mg,FastP1: C2: Placebo,Fast/PF-07817883 3000mg,Fast/Placebo,FedP1: C2: PF-07817883 500mg,Fast/Placebo,Fast/PF-07817883 500mg,FedP1: C2: PF-07817883 500mg,Fast/PF-07817883 3000mg,Fast/PF-07817883 500mg,FedPart 2: Placebo (Suspension) BID, FastedPart 2: PF-07817883 200 mg (Suspension) BID, FastedPart 2: PF-07817883 600 mg (Suspension) BID, FastedPart 2: PF-07817883 1500 mg (Suspension) BID, FastedPart 2: Placebo (Suspension) BID, Fasted, ChinesePart 2: PF-07817883 600 mg (Suspension) BID, Fasted, ChinesePart 3: Treatment Sequence ABCDPart 3: Treatment Sequence BCADPart 3: Treatment Sequence CABDPart 3: Treatment Sequence BACEPart 3: Treatment Sequence ACBEPart 3: Treatment Sequence CBAEPart 4: PF-07817883 600 mg (Suspension), FastedPart 5: Treatment Sequence ABPart 5: Treatment Sequence BAPart 6: Treatment Sequence ABCPart 6: Treatment Sequence BCAPart 6: Treatment Sequence CABPart 6: Treatment Sequence BACPart 6: Treatment Sequence ACBPart 6: Treatment Sequence CBA
Started0000000000000222222000000000
Completed0000000000000222222000000000
Not completed0000000000000000000000000000
Part 3: Period 2 (Day 1)
Participant flow — Part 3: Period 2 (Day 1)
MilestoneP1: C1: Placebo,Fast/PF-07817883 1500mg,Fast/PF-07817883 4000mg, FastP1: C1: PF-07817883 150mg,Fast/Placebo,Fast/PF-07817883 4000mg,FastP1: C1: PF-07817883 150 mg,Fast/PF-07817883 1500mg,Fast/Placebo,FastP1: C1: PF-07817883 150 mg,Fast/PF-07817883 1500mg,Fast/PF-07817883 4000mg,FastP1: C2: Placebo,Fast/PF-07817883 3000mg,Fast/Placebo,FedP1: C2: PF-07817883 500mg,Fast/Placebo,Fast/PF-07817883 500mg,FedP1: C2: PF-07817883 500mg,Fast/PF-07817883 3000mg,Fast/PF-07817883 500mg,FedPart 2: Placebo (Suspension) BID, FastedPart 2: PF-07817883 200 mg (Suspension) BID, FastedPart 2: PF-07817883 600 mg (Suspension) BID, FastedPart 2: PF-07817883 1500 mg (Suspension) BID, FastedPart 2: Placebo (Suspension) BID, Fasted, ChinesePart 2: PF-07817883 600 mg (Suspension) BID, Fasted, ChinesePart 3: Treatment Sequence ABCDPart 3: Treatment Sequence BCADPart 3: Treatment Sequence CABDPart 3: Treatment Sequence BACEPart 3: Treatment Sequence ACBEPart 3: Treatment Sequence CBAEPart 4: PF-07817883 600 mg (Suspension), FastedPart 5: Treatment Sequence ABPart 5: Treatment Sequence BAPart 6: Treatment Sequence ABCPart 6: Treatment Sequence BCAPart 6: Treatment Sequence CABPart 6: Treatment Sequence BACPart 6: Treatment Sequence ACBPart 6: Treatment Sequence CBA
Started0000000000000222222000000000
Completed0000000000000222222000000000
Not completed0000000000000000000000000000
Part 3: Washout 2 (up to 3 Days)
Participant flow — Part 3: Washout 2 (up to 3 Days)
MilestoneP1: C1: Placebo,Fast/PF-07817883 1500mg,Fast/PF-07817883 4000mg, FastP1: C1: PF-07817883 150mg,Fast/Placebo,Fast/PF-07817883 4000mg,FastP1: C1: PF-07817883 150 mg,Fast/PF-07817883 1500mg,Fast/Placebo,FastP1: C1: PF-07817883 150 mg,Fast/PF-07817883 1500mg,Fast/PF-07817883 4000mg,FastP1: C2: Placebo,Fast/PF-07817883 3000mg,Fast/Placebo,FedP1: C2: PF-07817883 500mg,Fast/Placebo,Fast/PF-07817883 500mg,FedP1: C2: PF-07817883 500mg,Fast/PF-07817883 3000mg,Fast/PF-07817883 500mg,FedPart 2: Placebo (Suspension) BID, FastedPart 2: PF-07817883 200 mg (Suspension) BID, FastedPart 2: PF-07817883 600 mg (Suspension) BID, FastedPart 2: PF-07817883 1500 mg (Suspension) BID, FastedPart 2: Placebo (Suspension) BID, Fasted, ChinesePart 2: PF-07817883 600 mg (Suspension) BID, Fasted, ChinesePart 3: Treatment Sequence ABCDPart 3: Treatment Sequence BCADPart 3: Treatment Sequence CABDPart 3: Treatment Sequence BACEPart 3: Treatment Sequence ACBEPart 3: Treatment Sequence CBAEPart 4: PF-07817883 600 mg (Suspension), FastedPart 5: Treatment Sequence ABPart 5: Treatment Sequence BAPart 6: Treatment Sequence ABCPart 6: Treatment Sequence BCAPart 6: Treatment Sequence CABPart 6: Treatment Sequence BACPart 6: Treatment Sequence ACBPart 6: Treatment Sequence CBA
Started0000000000000222222000000000
Completed0000000000000222222000000000
Not completed0000000000000000000000000000
Part 3: Period 3 (Day 1)
Participant flow — Part 3: Period 3 (Day 1)
MilestoneP1: C1: Placebo,Fast/PF-07817883 1500mg,Fast/PF-07817883 4000mg, FastP1: C1: PF-07817883 150mg,Fast/Placebo,Fast/PF-07817883 4000mg,FastP1: C1: PF-07817883 150 mg,Fast/PF-07817883 1500mg,Fast/Placebo,FastP1: C1: PF-07817883 150 mg,Fast/PF-07817883 1500mg,Fast/PF-07817883 4000mg,FastP1: C2: Placebo,Fast/PF-07817883 3000mg,Fast/Placebo,FedP1: C2: PF-07817883 500mg,Fast/Placebo,Fast/PF-07817883 500mg,FedP1: C2: PF-07817883 500mg,Fast/PF-07817883 3000mg,Fast/PF-07817883 500mg,FedPart 2: Placebo (Suspension) BID, FastedPart 2: PF-07817883 200 mg (Suspension) BID, FastedPart 2: PF-07817883 600 mg (Suspension) BID, FastedPart 2: PF-07817883 1500 mg (Suspension) BID, FastedPart 2: Placebo (Suspension) BID, Fasted, ChinesePart 2: PF-07817883 600 mg (Suspension) BID, Fasted, ChinesePart 3: Treatment Sequence ABCDPart 3: Treatment Sequence BCADPart 3: Treatment Sequence CABDPart 3: Treatment Sequence BACEPart 3: Treatment Sequence ACBEPart 3: Treatment Sequence CBAEPart 4: PF-07817883 600 mg (Suspension), FastedPart 5: Treatment Sequence ABPart 5: Treatment Sequence BAPart 6: Treatment Sequence ABCPart 6: Treatment Sequence BCAPart 6: Treatment Sequence CABPart 6: Treatment Sequence BACPart 6: Treatment Sequence ACBPart 6: Treatment Sequence CBA
Started0000000000000222222000000000
Completed0000000000000222222000000000
Not completed0000000000000000000000000000
Part 3: Washout 3 (up to 3 Days)
Participant flow — Part 3: Washout 3 (up to 3 Days)
MilestoneP1: C1: Placebo,Fast/PF-07817883 1500mg,Fast/PF-07817883 4000mg, FastP1: C1: PF-07817883 150mg,Fast/Placebo,Fast/PF-07817883 4000mg,FastP1: C1: PF-07817883 150 mg,Fast/PF-07817883 1500mg,Fast/Placebo,FastP1: C1: PF-07817883 150 mg,Fast/PF-07817883 1500mg,Fast/PF-07817883 4000mg,FastP1: C2: Placebo,Fast/PF-07817883 3000mg,Fast/Placebo,FedP1: C2: PF-07817883 500mg,Fast/Placebo,Fast/PF-07817883 500mg,FedP1: C2: PF-07817883 500mg,Fast/PF-07817883 3000mg,Fast/PF-07817883 500mg,FedPart 2: Placebo (Suspension) BID, FastedPart 2: PF-07817883 200 mg (Suspension) BID, FastedPart 2: PF-07817883 600 mg (Suspension) BID, FastedPart 2: PF-07817883 1500 mg (Suspension) BID, FastedPart 2: Placebo (Suspension) BID, Fasted, ChinesePart 2: PF-07817883 600 mg (Suspension) BID, Fasted, ChinesePart 3: Treatment Sequence ABCDPart 3: Treatment Sequence BCADPart 3: Treatment Sequence CABDPart 3: Treatment Sequence BACEPart 3: Treatment Sequence ACBEPart 3: Treatment Sequence CBAEPart 4: PF-07817883 600 mg (Suspension), FastedPart 5: Treatment Sequence ABPart 5: Treatment Sequence BAPart 6: Treatment Sequence ABCPart 6: Treatment Sequence BCAPart 6: Treatment Sequence CABPart 6: Treatment Sequence BACPart 6: Treatment Sequence ACBPart 6: Treatment Sequence CBA
Started0000000000000222222000000000
Completed0000000000000222222000000000
Not completed0000000000000000000000000000
Part 3: Period 4 (Day 1)
Participant flow — Part 3: Period 4 (Day 1)
MilestoneP1: C1: Placebo,Fast/PF-07817883 1500mg,Fast/PF-07817883 4000mg, FastP1: C1: PF-07817883 150mg,Fast/Placebo,Fast/PF-07817883 4000mg,FastP1: C1: PF-07817883 150 mg,Fast/PF-07817883 1500mg,Fast/Placebo,FastP1: C1: PF-07817883 150 mg,Fast/PF-07817883 1500mg,Fast/PF-07817883 4000mg,FastP1: C2: Placebo,Fast/PF-07817883 3000mg,Fast/Placebo,FedP1: C2: PF-07817883 500mg,Fast/Placebo,Fast/PF-07817883 500mg,FedP1: C2: PF-07817883 500mg,Fast/PF-07817883 3000mg,Fast/PF-07817883 500mg,FedPart 2: Placebo (Suspension) BID, FastedPart 2: PF-07817883 200 mg (Suspension) BID, FastedPart 2: PF-07817883 600 mg (Suspension) BID, FastedPart 2: PF-07817883 1500 mg (Suspension) BID, FastedPart 2: Placebo (Suspension) BID, Fasted, ChinesePart 2: PF-07817883 600 mg (Suspension) BID, Fasted, ChinesePart 3: Treatment Sequence ABCDPart 3: Treatment Sequence BCADPart 3: Treatment Sequence CABDPart 3: Treatment Sequence BACEPart 3: Treatment Sequence ACBEPart 3: Treatment Sequence CBAEPart 4: PF-07817883 600 mg (Suspension), FastedPart 5: Treatment Sequence ABPart 5: Treatment Sequence BAPart 6: Treatment Sequence ABCPart 6: Treatment Sequence BCAPart 6: Treatment Sequence CABPart 6: Treatment Sequence BACPart 6: Treatment Sequence ACBPart 6: Treatment Sequence CBA
Started0000000000000222222000000000
Completed0000000000000222222000000000
Not completed0000000000000000000000000000
Part 4 (Day 1 to Day 11)
Participant flow — Part 4 (Day 1 to Day 11)
MilestoneP1: C1: Placebo,Fast/PF-07817883 1500mg,Fast/PF-07817883 4000mg, FastP1: C1: PF-07817883 150mg,Fast/Placebo,Fast/PF-07817883 4000mg,FastP1: C1: PF-07817883 150 mg,Fast/PF-07817883 1500mg,Fast/Placebo,FastP1: C1: PF-07817883 150 mg,Fast/PF-07817883 1500mg,Fast/PF-07817883 4000mg,FastP1: C2: Placebo,Fast/PF-07817883 3000mg,Fast/Placebo,FedP1: C2: PF-07817883 500mg,Fast/Placebo,Fast/PF-07817883 500mg,FedP1: C2: PF-07817883 500mg,Fast/PF-07817883 3000mg,Fast/PF-07817883 500mg,FedPart 2: Placebo (Suspension) BID, FastedPart 2: PF-07817883 200 mg (Suspension) BID, FastedPart 2: PF-07817883 600 mg (Suspension) BID, FastedPart 2: PF-07817883 1500 mg (Suspension) BID, FastedPart 2: Placebo (Suspension) BID, Fasted, ChinesePart 2: PF-07817883 600 mg (Suspension) BID, Fasted, ChinesePart 3: Treatment Sequence ABCDPart 3: Treatment Sequence BCADPart 3: Treatment Sequence CABDPart 3: Treatment Sequence BACEPart 3: Treatment Sequence ACBEPart 3: Treatment Sequence CBAEPart 4: PF-07817883 600 mg (Suspension), FastedPart 5: Treatment Sequence ABPart 5: Treatment Sequence BAPart 6: Treatment Sequence ABCPart 6: Treatment Sequence BCAPart 6: Treatment Sequence CABPart 6: Treatment Sequence BACPart 6: Treatment Sequence ACBPart 6: Treatment Sequence CBA
Started0000000000000000000600000000
Completed0000000000000000000500000000
Not completed0000000000000000000100000000
Withdrew: Adverse event0000000000000000000100000000
Part 5: Sequence AB: Period 1 (Day 1)
Participant flow — Part 5: Sequence AB: Period 1 (Day 1)
MilestoneP1: C1: Placebo,Fast/PF-07817883 1500mg,Fast/PF-07817883 4000mg, FastP1: C1: PF-07817883 150mg,Fast/Placebo,Fast/PF-07817883 4000mg,FastP1: C1: PF-07817883 150 mg,Fast/PF-07817883 1500mg,Fast/Placebo,FastP1: C1: PF-07817883 150 mg,Fast/PF-07817883 1500mg,Fast/PF-07817883 4000mg,FastP1: C2: Placebo,Fast/PF-07817883 3000mg,Fast/Placebo,FedP1: C2: PF-07817883 500mg,Fast/Placebo,Fast/PF-07817883 500mg,FedP1: C2: PF-07817883 500mg,Fast/PF-07817883 3000mg,Fast/PF-07817883 500mg,FedPart 2: Placebo (Suspension) BID, FastedPart 2: PF-07817883 200 mg (Suspension) BID, FastedPart 2: PF-07817883 600 mg (Suspension) BID, FastedPart 2: PF-07817883 1500 mg (Suspension) BID, FastedPart 2: Placebo (Suspension) BID, Fasted, ChinesePart 2: PF-07817883 600 mg (Suspension) BID, Fasted, ChinesePart 3: Treatment Sequence ABCDPart 3: Treatment Sequence BCADPart 3: Treatment Sequence CABDPart 3: Treatment Sequence BACEPart 3: Treatment Sequence ACBEPart 3: Treatment Sequence CBAEPart 4: PF-07817883 600 mg (Suspension), FastedPart 5: Treatment Sequence ABPart 5: Treatment Sequence BAPart 6: Treatment Sequence ABCPart 6: Treatment Sequence BCAPart 6: Treatment Sequence CABPart 6: Treatment Sequence BACPart 6: Treatment Sequence ACBPart 6: Treatment Sequence CBA
Started0000000000000000000070000000
Completed0000000000000000000060000000
Not completed0000000000000000000010000000
Withdrew: Adverse event0000000000000000000010000000
Part 5:SequenceAB:Washout1(Upto 2 Days)
Participant flow — Part 5:SequenceAB:Washout1(Upto 2 Days)
MilestoneP1: C1: Placebo,Fast/PF-07817883 1500mg,Fast/PF-07817883 4000mg, FastP1: C1: PF-07817883 150mg,Fast/Placebo,Fast/PF-07817883 4000mg,FastP1: C1: PF-07817883 150 mg,Fast/PF-07817883 1500mg,Fast/Placebo,FastP1: C1: PF-07817883 150 mg,Fast/PF-07817883 1500mg,Fast/PF-07817883 4000mg,FastP1: C2: Placebo,Fast/PF-07817883 3000mg,Fast/Placebo,FedP1: C2: PF-07817883 500mg,Fast/Placebo,Fast/PF-07817883 500mg,FedP1: C2: PF-07817883 500mg,Fast/PF-07817883 3000mg,Fast/PF-07817883 500mg,FedPart 2: Placebo (Suspension) BID, FastedPart 2: PF-07817883 200 mg (Suspension) BID, FastedPart 2: PF-07817883 600 mg (Suspension) BID, FastedPart 2: PF-07817883 1500 mg (Suspension) BID, FastedPart 2: Placebo (Suspension) BID, Fasted, ChinesePart 2: PF-07817883 600 mg (Suspension) BID, Fasted, ChinesePart 3: Treatment Sequence ABCDPart 3: Treatment Sequence BCADPart 3: Treatment Sequence CABDPart 3: Treatment Sequence BACEPart 3: Treatment Sequence ACBEPart 3: Treatment Sequence CBAEPart 4: PF-07817883 600 mg (Suspension), FastedPart 5: Treatment Sequence ABPart 5: Treatment Sequence BAPart 6: Treatment Sequence ABCPart 6: Treatment Sequence BCAPart 6: Treatment Sequence CABPart 6: Treatment Sequence BACPart 6: Treatment Sequence ACBPart 6: Treatment Sequence CBA
Started0000000000000000000060000000
Completed0000000000000000000060000000
Not completed0000000000000000000000000000
Part5:SequenceAB:Period2(up to 10 Days)
Participant flow — Part5:SequenceAB:Period2(up to 10 Days)
MilestoneP1: C1: Placebo,Fast/PF-07817883 1500mg,Fast/PF-07817883 4000mg, FastP1: C1: PF-07817883 150mg,Fast/Placebo,Fast/PF-07817883 4000mg,FastP1: C1: PF-07817883 150 mg,Fast/PF-07817883 1500mg,Fast/Placebo,FastP1: C1: PF-07817883 150 mg,Fast/PF-07817883 1500mg,Fast/PF-07817883 4000mg,FastP1: C2: Placebo,Fast/PF-07817883 3000mg,Fast/Placebo,FedP1: C2: PF-07817883 500mg,Fast/Placebo,Fast/PF-07817883 500mg,FedP1: C2: PF-07817883 500mg,Fast/PF-07817883 3000mg,Fast/PF-07817883 500mg,FedPart 2: Placebo (Suspension) BID, FastedPart 2: PF-07817883 200 mg (Suspension) BID, FastedPart 2: PF-07817883 600 mg (Suspension) BID, FastedPart 2: PF-07817883 1500 mg (Suspension) BID, FastedPart 2: Placebo (Suspension) BID, Fasted, ChinesePart 2: PF-07817883 600 mg (Suspension) BID, Fasted, ChinesePart 3: Treatment Sequence ABCDPart 3: Treatment Sequence BCADPart 3: Treatment Sequence CABDPart 3: Treatment Sequence BACEPart 3: Treatment Sequence ACBEPart 3: Treatment Sequence CBAEPart 4: PF-07817883 600 mg (Suspension), FastedPart 5: Treatment Sequence ABPart 5: Treatment Sequence BAPart 6: Treatment Sequence ABCPart 6: Treatment Sequence BCAPart 6: Treatment Sequence CABPart 6: Treatment Sequence BACPart 6: Treatment Sequence ACBPart 6: Treatment Sequence CBA
Started0000000000000000000060000000
Completed0000000000000000000060000000
Not completed0000000000000000000000000000
Part5:Sequence AB:Washout2(up to 7 Days)
Participant flow — Part5:Sequence AB:Washout2(up to 7 Days)
MilestoneP1: C1: Placebo,Fast/PF-07817883 1500mg,Fast/PF-07817883 4000mg, FastP1: C1: PF-07817883 150mg,Fast/Placebo,Fast/PF-07817883 4000mg,FastP1: C1: PF-07817883 150 mg,Fast/PF-07817883 1500mg,Fast/Placebo,FastP1: C1: PF-07817883 150 mg,Fast/PF-07817883 1500mg,Fast/PF-07817883 4000mg,FastP1: C2: Placebo,Fast/PF-07817883 3000mg,Fast/Placebo,FedP1: C2: PF-07817883 500mg,Fast/Placebo,Fast/PF-07817883 500mg,FedP1: C2: PF-07817883 500mg,Fast/PF-07817883 3000mg,Fast/PF-07817883 500mg,FedPart 2: Placebo (Suspension) BID, FastedPart 2: PF-07817883 200 mg (Suspension) BID, FastedPart 2: PF-07817883 600 mg (Suspension) BID, FastedPart 2: PF-07817883 1500 mg (Suspension) BID, FastedPart 2: Placebo (Suspension) BID, Fasted, ChinesePart 2: PF-07817883 600 mg (Suspension) BID, Fasted, ChinesePart 3: Treatment Sequence ABCDPart 3: Treatment Sequence BCADPart 3: Treatment Sequence CABDPart 3: Treatment Sequence BACEPart 3: Treatment Sequence ACBEPart 3: Treatment Sequence CBAEPart 4: PF-07817883 600 mg (Suspension), FastedPart 5: Treatment Sequence ABPart 5: Treatment Sequence BAPart 6: Treatment Sequence ABCPart 6: Treatment Sequence BCAPart 6: Treatment Sequence CABPart 6: Treatment Sequence BACPart 6: Treatment Sequence ACBPart 6: Treatment Sequence CBA
Started0000000000000000000060000000
Completed0000000000000000000060000000
Not completed0000000000000000000000000000
Part5:Sequence BA:Period1(up to 10 Days)
Participant flow — Part5:Sequence BA:Period1(up to 10 Days)
MilestoneP1: C1: Placebo,Fast/PF-07817883 1500mg,Fast/PF-07817883 4000mg, FastP1: C1: PF-07817883 150mg,Fast/Placebo,Fast/PF-07817883 4000mg,FastP1: C1: PF-07817883 150 mg,Fast/PF-07817883 1500mg,Fast/Placebo,FastP1: C1: PF-07817883 150 mg,Fast/PF-07817883 1500mg,Fast/PF-07817883 4000mg,FastP1: C2: Placebo,Fast/PF-07817883 3000mg,Fast/Placebo,FedP1: C2: PF-07817883 500mg,Fast/Placebo,Fast/PF-07817883 500mg,FedP1: C2: PF-07817883 500mg,Fast/PF-07817883 3000mg,Fast/PF-07817883 500mg,FedPart 2: Placebo (Suspension) BID, FastedPart 2: PF-07817883 200 mg (Suspension) BID, FastedPart 2: PF-07817883 600 mg (Suspension) BID, FastedPart 2: PF-07817883 1500 mg (Suspension) BID, FastedPart 2: Placebo (Suspension) BID, Fasted, ChinesePart 2: PF-07817883 600 mg (Suspension) BID, Fasted, ChinesePart 3: Treatment Sequence ABCDPart 3: Treatment Sequence BCADPart 3: Treatment Sequence CABDPart 3: Treatment Sequence BACEPart 3: Treatment Sequence ACBEPart 3: Treatment Sequence CBAEPart 4: PF-07817883 600 mg (Suspension), FastedPart 5: Treatment Sequence ABPart 5: Treatment Sequence BAPart 6: Treatment Sequence ABCPart 6: Treatment Sequence BCAPart 6: Treatment Sequence CABPart 6: Treatment Sequence BACPart 6: Treatment Sequence ACBPart 6: Treatment Sequence CBA
Started0000000000000000000007000000
Completed0000000000000000000006000000
Not completed0000000000000000000001000000
Withdrew: Adverse event0000000000000000000001000000
Part5:Sequence BA:Washout1(up to 7 Days)
Participant flow — Part5:Sequence BA:Washout1(up to 7 Days)
MilestoneP1: C1: Placebo,Fast/PF-07817883 1500mg,Fast/PF-07817883 4000mg, FastP1: C1: PF-07817883 150mg,Fast/Placebo,Fast/PF-07817883 4000mg,FastP1: C1: PF-07817883 150 mg,Fast/PF-07817883 1500mg,Fast/Placebo,FastP1: C1: PF-07817883 150 mg,Fast/PF-07817883 1500mg,Fast/PF-07817883 4000mg,FastP1: C2: Placebo,Fast/PF-07817883 3000mg,Fast/Placebo,FedP1: C2: PF-07817883 500mg,Fast/Placebo,Fast/PF-07817883 500mg,FedP1: C2: PF-07817883 500mg,Fast/PF-07817883 3000mg,Fast/PF-07817883 500mg,FedPart 2: Placebo (Suspension) BID, FastedPart 2: PF-07817883 200 mg (Suspension) BID, FastedPart 2: PF-07817883 600 mg (Suspension) BID, FastedPart 2: PF-07817883 1500 mg (Suspension) BID, FastedPart 2: Placebo (Suspension) BID, Fasted, ChinesePart 2: PF-07817883 600 mg (Suspension) BID, Fasted, ChinesePart 3: Treatment Sequence ABCDPart 3: Treatment Sequence BCADPart 3: Treatment Sequence CABDPart 3: Treatment Sequence BACEPart 3: Treatment Sequence ACBEPart 3: Treatment Sequence CBAEPart 4: PF-07817883 600 mg (Suspension), FastedPart 5: Treatment Sequence ABPart 5: Treatment Sequence BAPart 6: Treatment Sequence ABCPart 6: Treatment Sequence BCAPart 6: Treatment Sequence CABPart 6: Treatment Sequence BACPart 6: Treatment Sequence ACBPart 6: Treatment Sequence CBA
Started0000000000000000000006000000
Completed0000000000000000000006000000
Not completed0000000000000000000000000000
Part 5: Sequence BA: Period 2 (Day 1)
Participant flow — Part 5: Sequence BA: Period 2 (Day 1)
MilestoneP1: C1: Placebo,Fast/PF-07817883 1500mg,Fast/PF-07817883 4000mg, FastP1: C1: PF-07817883 150mg,Fast/Placebo,Fast/PF-07817883 4000mg,FastP1: C1: PF-07817883 150 mg,Fast/PF-07817883 1500mg,Fast/Placebo,FastP1: C1: PF-07817883 150 mg,Fast/PF-07817883 1500mg,Fast/PF-07817883 4000mg,FastP1: C2: Placebo,Fast/PF-07817883 3000mg,Fast/Placebo,FedP1: C2: PF-07817883 500mg,Fast/Placebo,Fast/PF-07817883 500mg,FedP1: C2: PF-07817883 500mg,Fast/PF-07817883 3000mg,Fast/PF-07817883 500mg,FedPart 2: Placebo (Suspension) BID, FastedPart 2: PF-07817883 200 mg (Suspension) BID, FastedPart 2: PF-07817883 600 mg (Suspension) BID, FastedPart 2: PF-07817883 1500 mg (Suspension) BID, FastedPart 2: Placebo (Suspension) BID, Fasted, ChinesePart 2: PF-07817883 600 mg (Suspension) BID, Fasted, ChinesePart 3: Treatment Sequence ABCDPart 3: Treatment Sequence BCADPart 3: Treatment Sequence CABDPart 3: Treatment Sequence BACEPart 3: Treatment Sequence ACBEPart 3: Treatment Sequence CBAEPart 4: PF-07817883 600 mg (Suspension), FastedPart 5: Treatment Sequence ABPart 5: Treatment Sequence BAPart 6: Treatment Sequence ABCPart 6: Treatment Sequence BCAPart 6: Treatment Sequence CABPart 6: Treatment Sequence BACPart 6: Treatment Sequence ACBPart 6: Treatment Sequence CBA
Started0000000000000000000006000000
Completed0000000000000000000006000000
Not completed0000000000000000000000000000
Part5:Sequence BA:Washout2(up to 2 Days)
Participant flow — Part5:Sequence BA:Washout2(up to 2 Days)
MilestoneP1: C1: Placebo,Fast/PF-07817883 1500mg,Fast/PF-07817883 4000mg, FastP1: C1: PF-07817883 150mg,Fast/Placebo,Fast/PF-07817883 4000mg,FastP1: C1: PF-07817883 150 mg,Fast/PF-07817883 1500mg,Fast/Placebo,FastP1: C1: PF-07817883 150 mg,Fast/PF-07817883 1500mg,Fast/PF-07817883 4000mg,FastP1: C2: Placebo,Fast/PF-07817883 3000mg,Fast/Placebo,FedP1: C2: PF-07817883 500mg,Fast/Placebo,Fast/PF-07817883 500mg,FedP1: C2: PF-07817883 500mg,Fast/PF-07817883 3000mg,Fast/PF-07817883 500mg,FedPart 2: Placebo (Suspension) BID, FastedPart 2: PF-07817883 200 mg (Suspension) BID, FastedPart 2: PF-07817883 600 mg (Suspension) BID, FastedPart 2: PF-07817883 1500 mg (Suspension) BID, FastedPart 2: Placebo (Suspension) BID, Fasted, ChinesePart 2: PF-07817883 600 mg (Suspension) BID, Fasted, ChinesePart 3: Treatment Sequence ABCDPart 3: Treatment Sequence BCADPart 3: Treatment Sequence CABDPart 3: Treatment Sequence BACEPart 3: Treatment Sequence ACBEPart 3: Treatment Sequence CBAEPart 4: PF-07817883 600 mg (Suspension), FastedPart 5: Treatment Sequence ABPart 5: Treatment Sequence BAPart 6: Treatment Sequence ABCPart 6: Treatment Sequence BCAPart 6: Treatment Sequence CABPart 6: Treatment Sequence BACPart 6: Treatment Sequence ACBPart 6: Treatment Sequence CBA
Started0000000000000000000006000000
Completed0000000000000000000006000000
Not completed0000000000000000000000000000
Part 6 Period 1 (Day 1)
Participant flow — Part 6 Period 1 (Day 1)
MilestoneP1: C1: Placebo,Fast/PF-07817883 1500mg,Fast/PF-07817883 4000mg, FastP1: C1: PF-07817883 150mg,Fast/Placebo,Fast/PF-07817883 4000mg,FastP1: C1: PF-07817883 150 mg,Fast/PF-07817883 1500mg,Fast/Placebo,FastP1: C1: PF-07817883 150 mg,Fast/PF-07817883 1500mg,Fast/PF-07817883 4000mg,FastP1: C2: Placebo,Fast/PF-07817883 3000mg,Fast/Placebo,FedP1: C2: PF-07817883 500mg,Fast/Placebo,Fast/PF-07817883 500mg,FedP1: C2: PF-07817883 500mg,Fast/PF-07817883 3000mg,Fast/PF-07817883 500mg,FedPart 2: Placebo (Suspension) BID, FastedPart 2: PF-07817883 200 mg (Suspension) BID, FastedPart 2: PF-07817883 600 mg (Suspension) BID, FastedPart 2: PF-07817883 1500 mg (Suspension) BID, FastedPart 2: Placebo (Suspension) BID, Fasted, ChinesePart 2: PF-07817883 600 mg (Suspension) BID, Fasted, ChinesePart 3: Treatment Sequence ABCDPart 3: Treatment Sequence BCADPart 3: Treatment Sequence CABDPart 3: Treatment Sequence BACEPart 3: Treatment Sequence ACBEPart 3: Treatment Sequence CBAEPart 4: PF-07817883 600 mg (Suspension), FastedPart 5: Treatment Sequence ABPart 5: Treatment Sequence BAPart 6: Treatment Sequence ABCPart 6: Treatment Sequence BCAPart 6: Treatment Sequence CABPart 6: Treatment Sequence BACPart 6: Treatment Sequence ACBPart 6: Treatment Sequence CBA
Started0000000000000000000000444444
Completed0000000000000000000000444444
Not completed0000000000000000000000000000
Part 6: Washout 1 (up to 7 Days)
Participant flow — Part 6: Washout 1 (up to 7 Days)
MilestoneP1: C1: Placebo,Fast/PF-07817883 1500mg,Fast/PF-07817883 4000mg, FastP1: C1: PF-07817883 150mg,Fast/Placebo,Fast/PF-07817883 4000mg,FastP1: C1: PF-07817883 150 mg,Fast/PF-07817883 1500mg,Fast/Placebo,FastP1: C1: PF-07817883 150 mg,Fast/PF-07817883 1500mg,Fast/PF-07817883 4000mg,FastP1: C2: Placebo,Fast/PF-07817883 3000mg,Fast/Placebo,FedP1: C2: PF-07817883 500mg,Fast/Placebo,Fast/PF-07817883 500mg,FedP1: C2: PF-07817883 500mg,Fast/PF-07817883 3000mg,Fast/PF-07817883 500mg,FedPart 2: Placebo (Suspension) BID, FastedPart 2: PF-07817883 200 mg (Suspension) BID, FastedPart 2: PF-07817883 600 mg (Suspension) BID, FastedPart 2: PF-07817883 1500 mg (Suspension) BID, FastedPart 2: Placebo (Suspension) BID, Fasted, ChinesePart 2: PF-07817883 600 mg (Suspension) BID, Fasted, ChinesePart 3: Treatment Sequence ABCDPart 3: Treatment Sequence BCADPart 3: Treatment Sequence CABDPart 3: Treatment Sequence BACEPart 3: Treatment Sequence ACBEPart 3: Treatment Sequence CBAEPart 4: PF-07817883 600 mg (Suspension), FastedPart 5: Treatment Sequence ABPart 5: Treatment Sequence BAPart 6: Treatment Sequence ABCPart 6: Treatment Sequence BCAPart 6: Treatment Sequence CABPart 6: Treatment Sequence BACPart 6: Treatment Sequence ACBPart 6: Treatment Sequence CBA
Started0000000000000000000000444444
Completed0000000000000000000000444444
Not completed0000000000000000000000000000
Part 6 Period 2 (Day 1)
Participant flow — Part 6 Period 2 (Day 1)
MilestoneP1: C1: Placebo,Fast/PF-07817883 1500mg,Fast/PF-07817883 4000mg, FastP1: C1: PF-07817883 150mg,Fast/Placebo,Fast/PF-07817883 4000mg,FastP1: C1: PF-07817883 150 mg,Fast/PF-07817883 1500mg,Fast/Placebo,FastP1: C1: PF-07817883 150 mg,Fast/PF-07817883 1500mg,Fast/PF-07817883 4000mg,FastP1: C2: Placebo,Fast/PF-07817883 3000mg,Fast/Placebo,FedP1: C2: PF-07817883 500mg,Fast/Placebo,Fast/PF-07817883 500mg,FedP1: C2: PF-07817883 500mg,Fast/PF-07817883 3000mg,Fast/PF-07817883 500mg,FedPart 2: Placebo (Suspension) BID, FastedPart 2: PF-07817883 200 mg (Suspension) BID, FastedPart 2: PF-07817883 600 mg (Suspension) BID, FastedPart 2: PF-07817883 1500 mg (Suspension) BID, FastedPart 2: Placebo (Suspension) BID, Fasted, ChinesePart 2: PF-07817883 600 mg (Suspension) BID, Fasted, ChinesePart 3: Treatment Sequence ABCDPart 3: Treatment Sequence BCADPart 3: Treatment Sequence CABDPart 3: Treatment Sequence BACEPart 3: Treatment Sequence ACBEPart 3: Treatment Sequence CBAEPart 4: PF-07817883 600 mg (Suspension), FastedPart 5: Treatment Sequence ABPart 5: Treatment Sequence BAPart 6: Treatment Sequence ABCPart 6: Treatment Sequence BCAPart 6: Treatment Sequence CABPart 6: Treatment Sequence BACPart 6: Treatment Sequence ACBPart 6: Treatment Sequence CBA
Started0000000000000000000000444444
Completed0000000000000000000000443443
Not completed0000000000000000000000001001
Withdrew: Adverse event0000000000000000000000000001
Withdrew: Other0000000000000000000000001000
Part 6: Washout 2 (up to 7 Days)
Participant flow — Part 6: Washout 2 (up to 7 Days)
MilestoneP1: C1: Placebo,Fast/PF-07817883 1500mg,Fast/PF-07817883 4000mg, FastP1: C1: PF-07817883 150mg,Fast/Placebo,Fast/PF-07817883 4000mg,FastP1: C1: PF-07817883 150 mg,Fast/PF-07817883 1500mg,Fast/Placebo,FastP1: C1: PF-07817883 150 mg,Fast/PF-07817883 1500mg,Fast/PF-07817883 4000mg,FastP1: C2: Placebo,Fast/PF-07817883 3000mg,Fast/Placebo,FedP1: C2: PF-07817883 500mg,Fast/Placebo,Fast/PF-07817883 500mg,FedP1: C2: PF-07817883 500mg,Fast/PF-07817883 3000mg,Fast/PF-07817883 500mg,FedPart 2: Placebo (Suspension) BID, FastedPart 2: PF-07817883 200 mg (Suspension) BID, FastedPart 2: PF-07817883 600 mg (Suspension) BID, FastedPart 2: PF-07817883 1500 mg (Suspension) BID, FastedPart 2: Placebo (Suspension) BID, Fasted, ChinesePart 2: PF-07817883 600 mg (Suspension) BID, Fasted, ChinesePart 3: Treatment Sequence ABCDPart 3: Treatment Sequence BCADPart 3: Treatment Sequence CABDPart 3: Treatment Sequence BACEPart 3: Treatment Sequence ACBEPart 3: Treatment Sequence CBAEPart 4: PF-07817883 600 mg (Suspension), FastedPart 5: Treatment Sequence ABPart 5: Treatment Sequence BAPart 6: Treatment Sequence ABCPart 6: Treatment Sequence BCAPart 6: Treatment Sequence CABPart 6: Treatment Sequence BACPart 6: Treatment Sequence ACBPart 6: Treatment Sequence CBA
Started0000000000000000000000443443
Completed0000000000000000000000443443
Not completed0000000000000000000000000000
Part 6 Period 3 (Day 1)
Participant flow — Part 6 Period 3 (Day 1)
MilestoneP1: C1: Placebo,Fast/PF-07817883 1500mg,Fast/PF-07817883 4000mg, FastP1: C1: PF-07817883 150mg,Fast/Placebo,Fast/PF-07817883 4000mg,FastP1: C1: PF-07817883 150 mg,Fast/PF-07817883 1500mg,Fast/Placebo,FastP1: C1: PF-07817883 150 mg,Fast/PF-07817883 1500mg,Fast/PF-07817883 4000mg,FastP1: C2: Placebo,Fast/PF-07817883 3000mg,Fast/Placebo,FedP1: C2: PF-07817883 500mg,Fast/Placebo,Fast/PF-07817883 500mg,FedP1: C2: PF-07817883 500mg,Fast/PF-07817883 3000mg,Fast/PF-07817883 500mg,FedPart 2: Placebo (Suspension) BID, FastedPart 2: PF-07817883 200 mg (Suspension) BID, FastedPart 2: PF-07817883 600 mg (Suspension) BID, FastedPart 2: PF-07817883 1500 mg (Suspension) BID, FastedPart 2: Placebo (Suspension) BID, Fasted, ChinesePart 2: PF-07817883 600 mg (Suspension) BID, Fasted, ChinesePart 3: Treatment Sequence ABCDPart 3: Treatment Sequence BCADPart 3: Treatment Sequence CABDPart 3: Treatment Sequence BACEPart 3: Treatment Sequence ACBEPart 3: Treatment Sequence CBAEPart 4: PF-07817883 600 mg (Suspension), FastedPart 5: Treatment Sequence ABPart 5: Treatment Sequence BAPart 6: Treatment Sequence ABCPart 6: Treatment Sequence BCAPart 6: Treatment Sequence CABPart 6: Treatment Sequence BACPart 6: Treatment Sequence ACBPart 6: Treatment Sequence CBA
Started0000000000000000000000443443
Completed0000000000000000000000443443
Not completed0000000000000000000000000000

Outcome measures

PrimaryPart 1: Number of Participants With Treatment Emergent Adverse Events (TEAEs)

An adverse event (AE) was any untoward medical occurrence in a participant temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE was considered a TEAE if the event started during the effective duration of treatment. All events that started on or after the first dosing day and time/start time, if collected, but before the end of the study were considered as TEAEs.

Time frame:
From start of study treatment up to 28-35 days after administration of last dose of study intervention (maximum up to 48 days)
Reported as:
Count of participants · Participants
Part 1: Number of Participants With Treatment Emergent Adverse Events (TEAEs)
ParticipantsPlacebo (Suspension), FastedPlacebo (Suspension), FedPF-07817883 150 mg (Suspension), FastedPF-07817883 500 mg (Suspension), FastedPF-07817883 500 mg (Suspension), FedPF-07817883 1500 mg (Suspension), FastedPF-07817883 3000 mg (Suspension), FastedPF-07817883 4000 mg (Suspension), Fasted
Part 1: Number of Participants With Treatment Emergent Adverse Events (TEAEs)41210301
PrimaryPart 1: Number of Participants With Laboratory Test Abnormalities

Laboratory parameters included: (lymphocytes less than (\<) 0.8\*lower limit of normal \[LLN\] \[10\^3 per millimeter cube {mm3}\], lymphocytes/leukocytes \<0.8\*LLN \[percentage {%}\], neutrophils \<0.8\*LLN \[10\^3/mm3\], neutrophils/leukocytes \<0.8\*LLN \[%\], monocytes/leukocytes greater than (\>) 1.2\*upper limit of normal \[ULN\] \[%\], partial thromboplastin time \>1.1\*ULN \[seconds\]), chemistry (bicarbonate \<0.9\*LLN \[milliequivalents per liter {mEq/L}\], creatine kinase \>2.0\*ULN \[units per liter {U/L}\], lipase \>1.5\*ULN \[U/L\]), and urinalysis (urine hemoglobin greater than or equal to \[\>=\] 1, leukocyte esterase \>=1). Number of participants with any lab test abnormalities meeting the pre-specified criteria are reported in this outcome measure.

Time frame:
From start of study treatment up to 28-35 days after administration of last dose of study intervention (maximum up to 48 days)
Reported as:
Count of participants · Participants
Part 1: Number of Participants With Laboratory Test Abnormalities
ParticipantsPlacebo (Suspension), FastedPlacebo (Suspension), FedPF-07817883 150 mg (Suspension), FastedPF-07817883 500 mg (Suspension), FastedPF-07817883 500 mg (Suspension), FedPF-07817883 1500 mg (Suspension), FastedPF-07817883 3000 mg (Suspension), FastedPF-07817883 4000 mg (Suspension), Fasted
Part 1: Number of Participants With Laboratory Test Abnormalities51221122
PrimaryPart 1: Number of Participants With Vital Signs Meeting Pre-Defined Criteria

Vital signs including systolic blood pressure (SBP), diastolic blood pressure (DBP) and pulse rate (PR) were measured in a supine position after approximately 5 minutes of rest for the participant. Criteria for vital signs included: SBP: value less than (\<) 90 millimeter of mercury (mmHg), change greater than or equal to (\>=) 30 mmHg increase, change \>= 30 mmHg decrease; DBP: value \< 50 mmHg, change \>= 20 mmHg increase, change \>= 20 mmHg decrease; PR: value \< 40 beats per minute (bpm), value \> 120 bpm.

Time frame:
Up to Day 2 of each period
Reported as:
Count of participants · Participants
Part 1: Number of Participants With Vital Signs Meeting Pre-Defined Criteria
ParticipantsPlacebo (Suspension), FastedPlacebo (Suspension), FedPF-07817883 150 mg (Suspension), FastedPF-07817883 500 mg (Suspension), FastedPF-07817883 500 mg (Suspension), FedPF-07817883 1500 mg (Suspension), FastedPF-07817883 3000 mg (Suspension), FastedPF-07817883 4000 mg (Suspension), Fasted
SBP value < 90 mmHg00011010
SBP Change >= 30 mmHg increase00001000
SBP Change >= 30 mmHg decrease00210000
DBP Value < 50 mmHg00000000
DBP Change >= 20 mmHg increase00000000
DBP Change >= 20 mmHg decrease00000000
PR Value < 40 bpm00000000
PR Value > 120 bpm00000000
PrimaryPart 1: Number of Participants With Electrocardiogram (ECG) Abnormalities

Standard 12 lead ECGs were obtained with the participant in a supine position after at least 5 minutes of rest using an ECG machine that automatically calculated the heart rate and measured PR interval, QT interval, QTcF and QRS complex. Number of participants with abnormalities in ECG were reported in this outcome measure.

Time frame:
Up to Day 2 of each period
Reported as:
Count of participants · Participants
Part 1: Number of Participants With Electrocardiogram (ECG) Abnormalities
ParticipantsPlacebo (Suspension), FastedPlacebo (Suspension), FedPF-07817883 150 mg (Suspension), FastedPF-07817883 500 mg (Suspension), FastedPF-07817883 500 mg (Suspension), FedPF-07817883 1500 mg (Suspension), FastedPF-07817883 3000 mg (Suspension), FastedPF-07817883 4000 mg (Suspension), Fasted
Part 1: Number of Participants With Electrocardiogram (ECG) Abnormalities00000000
PrimaryPart 2: Number of Participants With Treatment Emergent Adverse Events (TEAEs)

An AE was any untoward medical occurrence in a participant temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE was considered a TEAE if the event started during the effective duration of treatment. All events that started on or after the first dosing day and time/start time, if collected, but before the end of the study were considered as TEAEs.

Time frame:
From start of study treatment up to 38-45 days after administration of last dose of study intervention (maximum up to 55 days)
Reported as:
Count of participants · Participants
Part 2: Number of Participants With Treatment Emergent Adverse Events (TEAEs)
ParticipantsPart 2: Placebo (Suspension) BID, FastedPart 2: PF-07817883 200 mg (Suspension) BID, FastedPart 2: PF-07817883 600 mg (Suspension) BID, FastedPart 2: PF-07817883 1500 mg (Suspension) BID, FastedPart 2: Placebo (Suspension) BID, Fasted, ChinesePart 2: PF-07817883 600 mg (Suspension) BID, Fasted, Chinese
Part 2: Number of Participants With Treatment Emergent Adverse Events (TEAEs)210202
PrimaryPart 2: Number of Participants With Laboratory Test Abnormalities

Laboratory parameters included: hematology (lymphocytes/leukocytes \>1.2\*ULN \[%\], neutrophils \<0.8\*LLN \[10\^3/mm3\], neutrophils/leukocytes \<0.8\*LLN \[%\], monocytes/leukocytes \>1.2\*ULN \[%\]), chemistry (urate \>1.2\*ULN \[milligrams per deciliter\] {mg/dL}), and urinalysis (ketones \>=1, urine hemoglobin \>=1). Number of participants with any lab test abnormalities meeting the pre-specified criteria are reported in this outcome measure.

Time frame:
From start of study treatment up to 38-45 days after administration of last dose of study intervention (maximum up to 55 days)
Reported as:
Count of participants · Participants
Part 2: Number of Participants With Laboratory Test Abnormalities
ParticipantsPart 2: Placebo (Suspension) BID, FastedPart 2: PF-07817883 200 mg (Suspension) BID, FastedPart 2: PF-07817883 600 mg (Suspension) BID, FastedPart 2: PF-07817883 1500 mg (Suspension) BID, FastedPart 2: Placebo (Suspension) BID, Fasted, ChinesePart 2: PF-07817883 600 mg (Suspension) BID, Fasted, Chinese
Part 2: Number of Participants With Laboratory Test Abnormalities122201
PrimaryPart 2: Number of Participants With Vital Signs Meeting Pre-Defined Criteria

Vital signs including SBP, DBP and PR were measured in a supine position after approximately 5 minutes of rest for the participant. Criteria for vital signs included: SBP: value \< 90 mmHg, change \>= 30 mmHg increase, change \>= 30 mmHg decrease; DBP: value \< 50 mmHg, change \>= 20 mmHg increase, change \>= 20 mmHg decrease; PR: value \< 40 bpm, value \> 120 bpm. 4. Number of participants with vital signs meeting any of the pre-defined criteria is reported in this outcome measure.

Time frame:
Up to Day 12
Reported as:
Count of participants · Participants
Part 2: Number of Participants With Vital Signs Meeting Pre-Defined Criteria
ParticipantsPart 2: Placebo (Suspension) BID, FastedPart 2: PF-07817883 200 mg (Suspension) BID, FastedPart 2: PF-07817883 600 mg (Suspension) BID, FastedPart 2: PF-07817883 1500 mg (Suspension) BID, FastedPart 2: Placebo (Suspension) BID, Fasted, ChinesePart 2: PF-07817883 600 mg (Suspension) BID, Fasted, Chinese
Part 2: Number of Participants With Vital Signs Meeting Pre-Defined Criteria000000
PrimaryPart 2: Number of Participants With Electrocardiogram (ECG) Abnormalities

Standard 12 lead ECGs were obtained with the participant in a supine position after at least 5 minutes of rest using an ECG machine that automatically calculated the heart rate and measured PR interval, QT interval, QTcF and QRS complex. Number of participants with abnormalities in ECG were reported in this outcome measure.

Time frame:
Up to Day 12
Reported as:
Count of participants · Participants
Part 2: Number of Participants With Electrocardiogram (ECG) Abnormalities
ParticipantsPart 2: Placebo (Suspension) BID, FastedPart 2: PF-07817883 200 mg (Suspension) BID, FastedPart 2: PF-07817883 600 mg (Suspension) BID, FastedPart 2: PF-07817883 1500 mg (Suspension) BID, FastedPart 2: Placebo (Suspension) BID, Fasted, ChinesePart 2: PF-07817883 600 mg (Suspension) BID, Fasted, Chinese
Part 2: Number of Participants With Electrocardiogram (ECG) Abnormalities000000
PrimaryPart 3:Ratio Based on Area Under Plasma Concentration Time Curve From Time 0 to Time of Last Quantifiable Concentration (AUClast) and Area Under Concentration-Time Curve From Time 0 Extrapolated to Infinite Time (AUCinf) of Oral Formulation and Suspension

Data for AUClast and AUCinf are reported in the descriptive section. AUClast was calculated by the linear/log trapezoidal method. AUCinf was calculated as AUClast + (Clast/kel), where Clast was the predicted plasma concentration at the last quantifiable time point from the log-linear regression analysis. Ratio based on AUClast and AUCinf of oral formulation and suspension were reported in statistical analysis.

Time frame:
Day 1 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48 hours post-dose)
Reported as:
Geometric mean · Nanogram*Hour per milliliter (ng*hr/mL)
Part 3:Ratio Based on Area Under Plasma Concentration Time Curve From Time 0 to Time of Last Quantifiable Concentration (AUClast) and Area Under Concentration-Time Curve From Time 0 Extrapolated to Infinite Time (AUCinf) of Oral Formulation and Suspension
Nanogram*Hour per milliliter (ng*hr/mL)Part 3: PF-07817883 600 mg (Suspension), FastedPart 3: PF-07817883 SDD 600 mg (Tablet), FastedPart 3: PF-07817883 SDD 600 mg (Tablet), FedPart 3: PF-07817883 Crystalline 600 mg (Tablet), FastedPart 3: PF-07817883 Crystalline 600 mg (Tablet), Fed
AUCinf42970 ± 3544140 ± 3828430 ± 2842930 ± 4346170 ± 27
AUClast42540 ± 3543570 ± 3727750 ± 2941620 ± 4135930 ± 54
Statistical analysis
  • Part 3: PF-07817883 600 mg (Suspension), Fasted vs Part 3: PF-07817883 Crystalline 600 mg (Tablet), Fasted · Ratio of adjusted geometric means: 101.29 · 90% CI 95.71 to 107.18A mixed effect model was used with sequence, period and treatment as fixed effect and participant nested within sequence as random effect. Values had been back-transformed from natural log scale. Ratios (and 90% CIs) were expressed as percentages.
  • Part 3: PF-07817883 600 mg (Suspension), Fasted vs Part 3: PF-07817883 SDD 600 mg (Tablet), Fasted · Ratio of adjusted geometric means: 102.74 · 90% CI 97.28 to 108.50A mixed effect model was used with sequence, period and treatment as fixed effect and participant nested within sequence as random effect. Values had been back-transformed from natural log scale. Ratios (and 90% CIs) were expressed as percentages.
  • Part 3: PF-07817883 600 mg (Suspension), Fasted vs Part 3: PF-07817883 Crystalline 600 mg (Tablet), Fasted · Ratio of adjusted geometric means: 97.83 · 90% CI 91.32 to 104.80A mixed effect model was used with sequence, period and treatment as fixed effect and participant nested within sequence as random effect. Values had been back-transformed from natural log scale. Ratios (and 90% CIs) were expressed as percentages.
  • Part 3: PF-07817883 600 mg (Suspension), Fasted vs Part 3: PF-07817883 SDD 600 mg (Tablet), Fasted · Ratio of adjusted geometric means: 102.41 · 90% CI 95.60 to 109.70A mixed effect model was used with sequence, period and treatment as fixed effect and participant nested within sequence as random effect. Values had been back-transformed from natural log scale. Ratios (and 90% CIs) were expressed as percentages.
PrimaryPart 3: Ratio Based on Maximum Observed Concentration (Cmax) of Oral Formulation and Suspension

Data for Cmax are reported in the descriptive section. Ratio based on Cmax of oral formulation and suspension were reported in statistical analysis.

Time frame:
Day 1 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48 hours post-dose)
Reported as:
Geometric mean · Nanogram per milliliter (ng/mL)
Part 3: Ratio Based on Maximum Observed Concentration (Cmax) of Oral Formulation and Suspension
Nanogram per milliliter (ng/mL)Part 3: PF-07817883 600 mg (Suspension), FastedPart 3: PF-07817883 SDD 600 mg (Tablet), FastedPart 3: PF-07817883 SDD 600 mg (Tablet), FedPart 3: PF-07817883 Crystalline 600 mg (Tablet), FastedPart 3: PF-07817883 Crystalline 600 mg (Tablet), Fed
Part 3: Ratio Based on Maximum Observed Concentration (Cmax) of Oral Formulation and Suspension9354 ± 186934 ± 354590 ± 216284 ± 385008 ± 47
Statistical analysis
  • Part 3: PF-07817883 600 mg (Suspension), Fasted vs Part 3: PF-07817883 Crystalline 600 mg (Tablet), Fasted · Ratio of adjusted geometric means: 67.18 · 90% CI 58.13 to 77.65A mixed effect model was used with sequence, period and treatment as fixed effect and participant nested within sequence as random effect. Values had been back-transformed from natural log scale. Ratios (and 90% CIs) were expressed as percentages.
  • Part 3: PF-07817883 600 mg (Suspension), Fasted vs Part 3: PF-07817883 SDD 600 mg (Tablet), Fasted · Ratio of adjusted geometric means: 74.12 · 90% CI 64.14 to 85.67A mixed effect model was used with sequence, period and treatment as fixed effect and participant nested within sequence as random effect. Values had been back-transformed from natural log scale. Ratios (and 90% CIs) were expressed as percentages.
PrimaryPart 4: Percentage of Total Dose Administered Recovered in Urine

The percentage of total dose administered recovered in urine was reported in this outcome measure.

Time frame:
Up to 144 hours post-dose
Reported as:
Mean · Percentage dose excreted
Part 4: Percentage of Total Dose Administered Recovered in Urine
Percentage dose excretedPart 4: PF-07817883 600 mg (Suspension), Fasted
Part 4: Percentage of Total Dose Administered Recovered in Urine12.6 ± 4.7
PrimaryPart 4: Percentage of Total Dose Administered Recovered in Feces

The percentage of total dose administered recovered in feces was reported in this outcome measure.

Time frame:
Up to 144 hours post-dose
Reported as:
Mean · Percentage dose excreted
Part 4: Percentage of Total Dose Administered Recovered in Feces
Percentage dose excretedPart 4: PF-07817883 600 mg (Suspension), Fasted
Part 4: Percentage of Total Dose Administered Recovered in Feces88.9 ± 10
PrimaryPart 4: Percentage of Total Dose Administered Recovered in Urine and Feces

The percentage of total dose administered recovered in urine and feces was reported in this outcome measure.

Time frame:
Up to 144 hours post-dose
Reported as:
Mean · Percentage dose excreted
Part 4: Percentage of Total Dose Administered Recovered in Urine and Feces
Percentage dose excretedPart 4: PF-07817883 600 mg (Suspension), Fasted
Part 4: Percentage of Total Dose Administered Recovered in Urine and Feces101.5 ± 7.7
PrimaryPart 5: Maximum Observed Concentration (Cmax) of Midazolam

Cmax of midazolam was reported in this outcome measure.

Time frame:
Day 1 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 36, 48 hours post-dose) for Midazolam 5 mg arm and Day 10 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 36, 48 hours post-dose) for PF-07817883 600 mg (Suspension) BID/ Midazolam 5 mg arm
Reported as:
Geometric mean · Nanogram per milliliter (ng/mL)
Part 5: Maximum Observed Concentration (Cmax) of Midazolam
Nanogram per milliliter (ng/mL)PF-07817883 600 mg (Suspension) BID/ Midazolam 5 mgMidazolam 5 mg
Part 5: Maximum Observed Concentration (Cmax) of Midazolam33.71 ± 3430.20 ± 28
PrimaryPart 5: Area Under the Concentration -Time Curve From Time Zero (0) Extrapolated to Infinite Time (AUCinf) of Midazolam

AUCinf of midazolam was reported in this outcome measure. AUCinf was calculated as AUClast + (Clast/kel), where Clast was the predicted plasma concentration at the last quantifiable time point from the log-linear regression analysis.

Time frame:
Day 1 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 36, 48 hours post-dose) for Midazolam 5 mg arm and Day 10 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 36, 48 hours post-dose) for PF-07817883 600 mg (Suspension) BID/ Midazolam 5 mg arm
Reported as:
Geometric mean · Nanogram*Hour per milliliter (ng*hr/mL)
Part 5: Area Under the Concentration -Time Curve From Time Zero (0) Extrapolated to Infinite Time (AUCinf) of Midazolam
Nanogram*Hour per milliliter (ng*hr/mL)PF-07817883 600 mg (Suspension) BID/ Midazolam 5 mgMidazolam 5 mg
Part 5: Area Under the Concentration -Time Curve From Time Zero (0) Extrapolated to Infinite Time (AUCinf) of Midazolam94.30 ± 2679.85 ± 31
PrimaryPart 6: Number of Participants With TEAEs

An AE was any untoward medical occurrence in a participant temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE was considered a TEAE if the event started during the effective duration of treatment. All events that started on or after the first dosing day and time/start time, if collected, but before the end of the study were considered as TEAEs.

Time frame:
From start of study treatment up to 28-35 days after administration of last dose of study intervention (maximum up to 52 days)
Reported as:
Count of participants · Participants
Part 6: Number of Participants With TEAEs
ParticipantsPlacebo (Suspension), FastedPF-07817883 6000 mg (Suspension), FastedMoxifloxacin 400 mg, Fasted
Part 6: Number of Participants With TEAEs464
PrimaryPart 6: Number of Participants With Laboratory Test Abnormalities

Laboratory parameters included: hematology (lymphocytes \<0.6\*LLN \[10\^3/mm3\], lymphocytes/leukocytes \>1.2\*ULN \[%\], neutrophils \<0.8\*LLN \[10\^3/mm3\], neutrophils/leukocytes \<0.8\*LLN \[%\], basophils/leukocytes \>1.2\*ULN \[%\], eosinophils/leukocytes \>1.2\*ULN \[%\], monocytes/leukocytes \>1.2\*ULN \[%\], partial thromboplastin time \>1.1\*ULN \[seconds\], prothrombin time \>1.1\*ULN \[seconds\]), chemistry (bicarbonate \<0.9\*LLN \[mEq/L\], creatine kinase \> 2.0\*ULN \[U/L\], lipase \> 1.5\*ULN \[U/L\], urobilinogen \>=1 \[ehrlich units/deciliter\] {EU/dL}) and urinalysis (urine hemoglobin \>=1, leukocyte esterase \>=1, ketones \>=1, bacteria \>20 \[per low power field\] {/lpf}). Number of participants with any lab test abnormalities meeting the pre-specified criteria are reported in this outcome measure.

Time frame:
From start of study treatment up to 28-35 days after administration of last dose of study intervention (maximum up to 52 days)
Reported as:
Count of participants · Participants
Part 6: Number of Participants With Laboratory Test Abnormalities
ParticipantsPlacebo (Suspension), FastedPF-07817883 6000 mg (Suspension), FastedMoxifloxacin 400 mg, Fasted
Part 6: Number of Participants With Laboratory Test Abnormalities12127
PrimaryPart 6: Number of Participants With Vital Signs Meeting Pre-Defined Criteria

Vital signs including SBP, DBP and PR were measured in a supine position after approximately 5 minutes of rest for the participant. Criteria for vital signs included: SBP: value \< 90 mmHg, change \>= 30 mmHg increase, change \>= 30 mmHg decrease; DBP: value \< 50 mmHg, change \>= 20 mmHg increase, change \>= 20 mmHg decrease; PR: value \< 40 bpm, value \> 120 bpm.

Time frame:
Up to Day 6 of each period
Reported as:
Count of participants · Participants
Part 6: Number of Participants With Vital Signs Meeting Pre-Defined Criteria
ParticipantsPlacebo (Suspension), FastedPF-07817883 6000 mg (Suspension), FastedMoxifloxacin 400 mg, Fasted
SBP value < 90 mmHg123
SBP change >= 30 mmHg increase010
SBP change >= 30 mmHg decrease000
DBP value < 50 mmHg000
DBP change >= 20 mmHg increase000
DBP change >= 20 mmHg decrease001
Pulse rate value < 40 bpm000
Pulse rate value > 120 bpm000
PrimaryPart 6: Number of Participants According to Categorization of ECG Data

Standard 12 lead ECGs were obtained with the participant in a supine position after at least 5 minutes of rest using an ECG machine that automatically calculated the heart rate and measured QTcF interval, aggregate 450 milliseconds (msec) \< value \<= 480 msec and QTcF interval, aggregate 30 msec \< change \<= 60 msec. Number of participants with abnormalities in ECG were reported in this outcome measure.

Time frame:
Up to Day 6 of each period
Reported as:
Count of participants · Participants
Part 6: Number of Participants According to Categorization of ECG Data
ParticipantsPlacebo (Suspension), FastedPF-07817883 6000 mg (Suspension), FastedMoxifloxacin 400 mg, Fasted
QTCF interval, aggregate 450 msec < Value <= 480 msec001
QTCF interval, aggregate 30 msec < Change <= 60 msec001
SecondaryPart 1: Maximum Observed Concentration (Cmax) of PF-07817883

Cmax of PF-07817883 was reported in this outcome measure.

Time frame:
Day 1 (pre-dose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48, 72 hours post-dose)
Reported as:
Geometric mean · Nanogram per milliliter (ng/mL)
Part 1: Maximum Observed Concentration (Cmax) of PF-07817883
Nanogram per milliliter (ng/mL)PF-07817883 150 mg (Suspension), FastedPF-07817883 500 mg (Suspension), FastedPF-07817883 500 mg (Suspension), FedPF-07817883 1500 mg (Suspension), FastedPF-07817883 3000 mg (Suspension), FastedPF-07817883 4000 mg (Suspension), Fasted
Part 1: Maximum Observed Concentration (Cmax) of PF-078178832269 ± 516235 ± 203223 ± 1317420 ± 3634420 ± 1234670 ± 36
SecondaryPart 1: Time for Cmax (Tmax) of PF-07817883

Tmax of PF-07817883 was reported in this outcome measure.

Time frame:
Day 1 (pre-dose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48, 72 hours post-dose)
Reported as:
Median · Hours
Part 1: Time for Cmax (Tmax) of PF-07817883
HoursPF-07817883 150 mg (Suspension), FastedPF-07817883 500 mg (Suspension), FastedPF-07817883 500 mg (Suspension), FedPF-07817883 1500 mg (Suspension), FastedPF-07817883 3000 mg (Suspension), FastedPF-07817883 4000 mg (Suspension), Fasted
Part 1: Time for Cmax (Tmax) of PF-078178831.00 (0.500 to 1.50)0.792 (0.500 to 1.50)1.25 (1.00 to 2.00)0.500 (0.500 to 1.00)0.500 (0.500 to 1.05)1.00 (0.550 to 1.50)
SecondaryPart 1: Area Under Plasma Concentration Time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of PF-07817883

AUClast of PF-07817883 was reported in this outcome measure. AUClast was calculated by the linear/log trapezoidal method.

Time frame:
Day 1 (pre-dose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48, 72 hours post-dose)
Reported as:
Geometric mean · Nanogram*hour per milliliter
Part 1: Area Under Plasma Concentration Time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of PF-07817883
Nanogram*hour per milliliterPF-07817883 150 mg (Suspension), FastedPF-07817883 500 mg (Suspension), FastedPF-07817883 500 mg (Suspension), FedPF-07817883 1500 mg (Suspension), FastedPF-07817883 3000 mg (Suspension), FastedPF-07817883 4000 mg (Suspension), Fasted
Part 1: Area Under Plasma Concentration Time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of PF-0781788310890 ± 4734580 ± 2527080 ± 2583490 ± 36160700 ± 33185700 ± 17
SecondaryPart 1: Dose Normalized Cmax (Cmax[dn]) of PF-07817883

Cmax(dn) of PF-07817883 was reported in this outcome measure. Cmax(dn) was calculated as Cmax/dose.

Time frame:
Day 1 (pre-dose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48, 72 hours post-dose)
Reported as:
Geometric mean · Nanogram per milliliter per milligram
Part 1: Dose Normalized Cmax (Cmax[dn]) of PF-07817883
Nanogram per milliliter per milligramPF-07817883 150 mg (Suspension), FastedPF-07817883 500 mg (Suspension), FastedPF-07817883 500 mg (Suspension), FedPF-07817883 1500 mg (Suspension), FastedPF-07817883 3000 mg (Suspension), FastedPF-07817883 4000 mg (Suspension), Fasted
Part 1: Dose Normalized Cmax (Cmax[dn]) of PF-0781788315.14 ± 5112.48 ± 196.445 ± 1311.61 ± 3611.49 ± 128.672 ± 36
SecondaryPart 1: Dose Normalized AUClast (AUClast[dn]) of PF-07817883

AUClast(dn) of PF-07817883 was reported in this outcome measure. AUClast(dn) was calculated by AUClast/dose.

Time frame:
Day 1 (pre-dose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48, 72 hours post-dose)
Reported as:
Geometric mean · Nanogram*hour/milliliter/milligram
Part 1: Dose Normalized AUClast (AUClast[dn]) of PF-07817883
Nanogram*hour/milliliter/milligramPF-07817883 150 mg (Suspension), FastedPF-07817883 500 mg (Suspension), FastedPF-07817883 500 mg (Suspension), FedPF-07817883 1500 mg (Suspension), FastedPF-07817883 3000 mg (Suspension), FastedPF-07817883 4000 mg (Suspension), Fasted
Part 1: Dose Normalized AUClast (AUClast[dn]) of PF-0781788372.61 ± 4769.17 ± 2554.16 ± 2555.64 ± 3553.53 ± 3346.43 ± 17
SecondaryPart 1: Area Under the Concentration -Time Curve From Time Zero (0) Extrapolated to Infinite Time (AUCinf) of PF-07817883

AUCinf of PF-07817883 was reported in this outcome measure. AUCinf was calculated as AUClast + (Clast/kel), where Clast was the predicted plasma concentration at the last quantifiable time point from the log-linear regression analysis.

Time frame:
Day 1 (pre-dose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48, 72 hours post-dose)
Reported as:
Geometric mean · Nanogram*hour/milliliter (ng*hr/mL)
Part 1: Area Under the Concentration -Time Curve From Time Zero (0) Extrapolated to Infinite Time (AUCinf) of PF-07817883
Nanogram*hour/milliliter (ng*hr/mL)PF-07817883 150 mg (Suspension), FastedPF-07817883 500 mg (Suspension), FastedPF-07817883 500 mg (Suspension), FedPF-07817883 1500 mg (Suspension), FastedPF-07817883 3000 mg (Suspension), FastedPF-07817883 4000 mg (Suspension), Fasted
Part 1: Area Under the Concentration -Time Curve From Time Zero (0) Extrapolated to Infinite Time (AUCinf) of PF-0781788311250 ± 5335950 ± 2528120 ± 2885320 ± 34166100 ± 34189400 ± 19
SecondaryPart 1: Dose Normalized AUCinf (AUCinf[dn]) of PF-07817883

AUCinf(dn) of PF-07817883 was reported in this outcome measure. AUCinf(dn) was calculated as AUCinf/dose.

Time frame:
Day 1 (pre-dose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48, 72 hours post-dose)
Reported as:
Geometric mean · Nanogram*hour/milliliter/milligram
Part 1: Dose Normalized AUCinf (AUCinf[dn]) of PF-07817883
Nanogram*hour/milliliter/milligramPF-07817883 150 mg (Suspension), FastedPF-07817883 500 mg (Suspension), FastedPF-07817883 500 mg (Suspension), FedPF-07817883 1500 mg (Suspension), FastedPF-07817883 3000 mg (Suspension), FastedPF-07817883 4000 mg (Suspension), Fasted
Part 1: Dose Normalized AUCinf (AUCinf[dn]) of PF-0781788374.99 ± 5371.81 ± 2556.23 ± 2856.86 ± 3455.33 ± 3547.34 ± 19
SecondaryPart 1: Terminal Half-Life (t1/2) of PF-07817883

t1/2 of PF-07817883 was reported in this outcome measure. t1/2 was calculated by Loge(2)/kel, where kel was the terminal phase rate constant calculated by a linear regression of the log linear concentration-time curve. Only those data points judged to describe the terminal log-linear decline were used in the regression.

Time frame:
Day 1 (pre-dose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48, 72 hours post-dose)
Reported as:
Mean · Hours
Part 1: Terminal Half-Life (t1/2) of PF-07817883
HoursPF-07817883 150 mg (Suspension), FastedPF-07817883 500 mg (Suspension), FastedPF-07817883 500 mg (Suspension), FedPF-07817883 1500 mg (Suspension), FastedPF-07817883 3000 mg (Suspension), FastedPF-07817883 4000 mg (Suspension), Fasted
Part 1: Terminal Half-Life (t1/2) of PF-078178834.534 ± 0.5065913.88 ± 10.83815.95 ± 8.465710.84 ± 6.174718.79 ± 14.23413.05 ± 7.3974
SecondaryPart 1: Apparent Volume of Distribution (Vz/F) of PF-07817883

Vz/F of PF-07817883 was reported in this outcome measure. Vz/F was calculated as dose/(AUCinf\*kel).

Time frame:
Day 1 (pre-dose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48, 72 hours post-dose)
Reported as:
Geometric mean · Liter (L)
Part 1: Apparent Volume of Distribution (Vz/F) of PF-07817883
Liter (L)PF-07817883 150 mg (Suspension), FastedPF-07817883 500 mg (Suspension), FastedPF-07817883 500 mg (Suspension), FedPF-07817883 1500 mg (Suspension), FastedPF-07817883 3000 mg (Suspension), FastedPF-07817883 4000 mg (Suspension), Fasted
Part 1: Apparent Volume of Distribution (Vz/F) of PF-0781788386.87 ± 48209.5 ± 101366.1 ± 50242.9 ± 80367.4 ± 87358.7 ± 44
SecondaryPart 1: Apparent Clearance (CL/F) of PF-07817883

CL/F of PF-07817883 was reported in this outcome measure. CL/F was calculated as dose/AUCinf.

Time frame:
Day 1 (pre-dose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48, 72 hours post-dose)
Reported as:
Geometric mean · Liter per hour (L/hr)
Part 1: Apparent Clearance (CL/F) of PF-07817883
Liter per hour (L/hr)PF-07817883 150 mg (Suspension), FastedPF-07817883 500 mg (Suspension), FastedPF-07817883 500 mg (Suspension), FedPF-07817883 1500 mg (Suspension), FastedPF-07817883 3000 mg (Suspension), FastedPF-07817883 4000 mg (Suspension), Fasted
Part 1: Apparent Clearance (CL/F) of PF-0781788313.33 ± 5313.93 ± 2517.79 ± 2817.58 ± 3518.09 ± 3521.13 ± 19
SecondaryPart 2: Maximum Observed Concentration (Cmax) of PF-07817883 on Days 1, 5 and 10

Cmax of PF-07817883 was reported in this outcome measure.

Time frame:
Day 1 and Day 5 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12 hours post-dose) and Day 10 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48 hours post-dose)
Reported as:
Geometric mean · Nanogram/milliliter
Part 2: Maximum Observed Concentration (Cmax) of PF-07817883 on Days 1, 5 and 10
Nanogram/milliliterPart 2: PF-07817883 200 mg (Suspension) BID, FastedPart 2: PF-07817883 600 mg (Suspension) BID, FastedPart 2: PF-07817883 1500 mg (Suspension) BID, FastedPart 2: PF-07817883 600 mg (Suspension) BID, Fasted, Chinese
Day 13582 ± 208470 ± 3924100 ± 228381 ± 12
Day 54234 ± 79112 ± 1427530 ± 228260 ± 18
Day 103492 ± 157852 ± 2123420 ± 147306 ± 25
SecondaryPart 2: Time for Cmax (Tmax) of PF-07817883 on Days 1, 5 and 10

Tmax of PF-07817883 was reported in this outcome measure.

Time frame:
Day 1 and Day 5 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12 hours post-dose) and Day 10 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48 hours post-dose)
Reported as:
Median · Hours
Part 2: Time for Cmax (Tmax) of PF-07817883 on Days 1, 5 and 10
HoursPart 2: PF-07817883 200 mg (Suspension) BID, FastedPart 2: PF-07817883 600 mg (Suspension) BID, FastedPart 2: PF-07817883 1500 mg (Suspension) BID, FastedPart 2: PF-07817883 600 mg (Suspension) BID, Fasted, Chinese
Day 10.759 (0.500 to 1.00)0.775 (0.500 to 1.00)0.500 (0.500 to 1.50)1.00 (1.00 to 1.05)
Day 50.859 (0.500 to 1.02)0.500 (0.500 to 0.500)0.500 (0.500 to 1.00)0.500 (0.500 to 1.00)
Day 100.500 (0.500 to 1.00)0.500 (0.500 to 1.00)0.500 (0.500 to 0.500)0.533 (0.500 to 1.00)
SecondaryPart 2: Area Under the Plasma Concentration-Time Profile From Time 0 to Time Tau, the Dosing Interval (AUCtau) of PF-07817883 on Days 1, 5 and 10

AUCtau was defined as area under the plasma concentration-time profile from time 0 to time tau, the dosing interval, where tau= 12 hours. AUCtau of PF-07817883 was reported in this outcome measure. AUCtau was calculated by linear/log trapezoidal method.

Time frame:
Day 1 and Day 5 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12 hours post-dose) and Day 10 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12 hours post-dose)
Reported as:
Geometric mean · Nanogram*hour per milliliter (ng*hr/mL)
Part 2: Area Under the Plasma Concentration-Time Profile From Time 0 to Time Tau, the Dosing Interval (AUCtau) of PF-07817883 on Days 1, 5 and 10
Nanogram*hour per milliliter (ng*hr/mL)Part 2: PF-07817883 200 mg (Suspension) BID, FastedPart 2: PF-07817883 600 mg (Suspension) BID, FastedPart 2: PF-07817883 1500 mg (Suspension) BID, FastedPart 2: PF-07817883 600 mg (Suspension) BID, Fasted, Chinese
Day 114760 ± 2636440 ± 27108400 ± 1536880 ± 22
Day 518460 ± 1536300 ± 10114000 ± 2237680 ± 29
Day 1017180 ± 1034960 ± 8103900 ± 1834650 ± 29
SecondaryPart 2: Concentration at 12 Hour Nominal Time Post-Dose (C12) of PF-07817883 on Days 5 and 10

C12 of PF-07817883 was reported in this outcome measure.

Time frame:
12 hours on Day 5 and Day 10
Reported as:
Geometric mean · Nanogram per milliliter (ng/mL)
Part 2: Concentration at 12 Hour Nominal Time Post-Dose (C12) of PF-07817883 on Days 5 and 10
Nanogram per milliliter (ng/mL)Part 2: PF-07817883 200 mg (Suspension) BID, FastedPart 2: PF-07817883 600 mg (Suspension) BID, FastedPart 2: PF-07817883 1500 mg (Suspension) BID, FastedPart 2: PF-07817883 600 mg (Suspension) BID, Fasted, Chinese
Day 5389.3 ± 15734.5 ± 152598 ± 47716.0 ± 47
Day 10425.7 ± 12865.9 ± 222315 ± 35585.5 ± 28
SecondaryPart 2: Dose Normalized Cmax (Cmax[dn]) of PF-07817883 on Days 1, 5 and 10

Cmax(dn) of PF-07817883 was reported in this outcome measure. Cmax(dn) was calculated as Cmax/dose.

Time frame:
Day 1 and Day 5 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12 hours post-dose) and Day 10 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48 hours post-dose)
Reported as:
Geometric mean · Nanogram/milliliter/milligram (ng/mL/mg)
Part 2: Dose Normalized Cmax (Cmax[dn]) of PF-07817883 on Days 1, 5 and 10
Nanogram/milliliter/milligram (ng/mL/mg)Part 2: PF-07817883 200 mg (Suspension) BID, FastedPart 2: PF-07817883 600 mg (Suspension) BID, FastedPart 2: PF-07817883 1500 mg (Suspension) BID, FastedPart 2: PF-07817883 600 mg (Suspension) BID, Fasted, Chinese
Day 117.93 ± 2014.15 ± 3916.07 ± 2214.00 ± 12
Day 521.18 ± 715.20 ± 1318.35 ± 2213.76 ± 18
Day 1017.47 ± 1513.07 ± 2115.61 ± 1412.20 ± 25
SecondaryPart 2: Dose Normalized AUCtau (AUCtau[dn]) of PF-07817883 on Days 1, 5 and 10

AUCtau(dn) was defined as dose normalized AUCtau, where tau= 12 hours. AUCtau(dn) of PF-07817883 was reported in this outcome measure. AUCtau(dn) was calculated as AUCtau/dose.

Time frame:
Day 1 and Day 5 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12 hours post-dose) and Day 10 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12 hours post-dose)
Reported as:
Geometric mean · Nanogram*hour/milliliter/milligram
Part 2: Dose Normalized AUCtau (AUCtau[dn]) of PF-07817883 on Days 1, 5 and 10
Nanogram*hour/milliliter/milligramPart 2: PF-07817883 200 mg (Suspension) BID, FastedPart 2: PF-07817883 600 mg (Suspension) BID, FastedPart 2: PF-07817883 1500 mg (Suspension) BID, FastedPart 2: PF-07817883 600 mg (Suspension) BID, Fasted, Chinese
Day 173.94 ± 2660.70 ± 2772.25 ± 1561.44 ± 22
Day 592.46 ± 1560.49 ± 1076.20 ± 2362.82 ± 29
Day 1086.04 ± 1058.28 ± 869.43 ± 1857.78 ± 29
SecondaryPart 2: Average Concentration (Cav) of PF-07817883 on Days 5 and 10

Cav of PF-07817883 was reported in this outcome measure. Cav was calculated as AUCtau/12.

Time frame:
Day 5 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12 hours post-dose) and Day 10 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12 hours post-dose)
Reported as:
Geometric mean · Nanogram/milliliter (ng/mL)
Part 2: Average Concentration (Cav) of PF-07817883 on Days 5 and 10
Nanogram/milliliter (ng/mL)Part 2: PF-07817883 200 mg (Suspension) BID, FastedPart 2: PF-07817883 600 mg (Suspension) BID, FastedPart 2: PF-07817883 1500 mg (Suspension) BID, FastedPart 2: PF-07817883 600 mg (Suspension) BID, Fasted, Chinese
Day 51542 ± 153022 ± 109515 ± 223140 ± 29
Day 101434 ± 102914 ± 88672 ± 182890 ± 29
SecondaryPart 2: Observed Accumulation Ratio for AUCtau (Rac) of PF-07817883 on Days 5 and 10

Rac was defined as observed accumulation ratio for AUCtau, where tau= 12 hours. Rac of PF-07817883 was reported in this outcome measure. Rac was calculated as AUCtau on Day 5 or Day 10/AUCtau on Day 1.

Time frame:
Day 5 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12 hours post-dose) and Day 10 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12 hours post-dose)
Reported as:
Geometric mean · Ratio
Part 2: Observed Accumulation Ratio for AUCtau (Rac) of PF-07817883 on Days 5 and 10
RatioPart 2: PF-07817883 200 mg (Suspension) BID, FastedPart 2: PF-07817883 600 mg (Suspension) BID, FastedPart 2: PF-07817883 1500 mg (Suspension) BID, FastedPart 2: PF-07817883 600 mg (Suspension) BID, Fasted, Chinese
Day 51.250 ± 280.9972 ± 181.054 ± 91.022 ± 7
Day 101.163 ± 180.8962 ± 200.9605 ± 40.9412 ± 8
SecondaryPart 2: Observed Accumulation Ratio for Cmax (Rac,Cmax) of PF-07817883 on Days 5 and 10

Rac,Cmax of PF-07817883 was reported in this outcome measure. Rac,Cmax was calculated as Cmax on Day 5 or Day 10/Cmax on Day 1.

Time frame:
Day 5 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12 hours post-dose) and Day 10 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48 hours post-dose)
Reported as:
Geometric mean · Ratio
Part 2: Observed Accumulation Ratio for Cmax (Rac,Cmax) of PF-07817883 on Days 5 and 10
RatioPart 2: PF-07817883 200 mg (Suspension) BID, FastedPart 2: PF-07817883 600 mg (Suspension) BID, FastedPart 2: PF-07817883 1500 mg (Suspension) BID, FastedPart 2: PF-07817883 600 mg (Suspension) BID, Fasted, Chinese
Day 51.183 ± 221.075 ± 301.142 ± 330.9844 ± 18
Day 100.9744 ± 200.8471 ± 360.9717 ± 180.8712 ± 21
SecondaryPart 2: Peak-to-Trough Ratio (PTR) of PF-07817883 on Days 5 and 10

PTR of PF-07817883 was reported in this outcome measure. PTR was calculated as Cmax/Cmin.

Time frame:
Day 5 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12 hours post-dose) and Day 10 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48 hours post-dose)
Reported as:
Geometric mean · Ratio
Part 2: Peak-to-Trough Ratio (PTR) of PF-07817883 on Days 5 and 10
RatioPart 2: PF-07817883 200 mg (Suspension) BID, FastedPart 2: PF-07817883 600 mg (Suspension) BID, FastedPart 2: PF-07817883 1500 mg (Suspension) BID, FastedPart 2: PF-07817883 600 mg (Suspension) BID, Fasted, Chinese
Day 510.88 ± 1013.47 ± 2110.60 ± 4913.22 ± 10
Day 108.566 ± 1411.05 ± 3010.13 ± 2312.46 ± 9
SecondaryPart 2: Apparent Clearance (CL/F) of PF-07817883 on Days 5 and 10

CL/F of PF-07817883 was reported in this outcome measure. CL/F was calculated as dose/AUCinf.

Time frame:
Day 5 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12 hours post-dose) and Day 10 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48 hours post-dose)
Reported as:
Geometric mean · Liter/hour (L/hr)
Part 2: Apparent Clearance (CL/F) of PF-07817883 on Days 5 and 10
Liter/hour (L/hr)Part 2: PF-07817883 200 mg (Suspension) BID, FastedPart 2: PF-07817883 600 mg (Suspension) BID, FastedPart 2: PF-07817883 1500 mg (Suspension) BID, FastedPart 2: PF-07817883 600 mg (Suspension) BID, Fasted, Chinese
Day 510.83 ± 1516.57 ± 1013.12 ± 2215.88 ± 29
Day 1011.60 ± 1017.13 ± 814.37 ± 1817.32 ± 29
SecondaryPart 2: Apparent Volume of Distribution (Vz/F) of PF-07817883 on Day 10

Vz/F of PF-07817883 was reported in this outcome measure. Vz/F was calculated as dose/(AUCtau\*kel).

Time frame:
Day 10 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48 hours post-dose)
Reported as:
Geometric mean · Liter
Part 2: Apparent Volume of Distribution (Vz/F) of PF-07817883 on Day 10
LiterPart 2: PF-07817883 200 mg (Suspension) BID, FastedPart 2: PF-07817883 600 mg (Suspension) BID, FastedPart 2: PF-07817883 1500 mg (Suspension) BID, FastedPart 2: PF-07817883 600 mg (Suspension) BID, Fasted, Chinese
Part 2: Apparent Volume of Distribution (Vz/F) of PF-07817883 on Day 10200.1 ± 84279.6 ± 62198.1 ± 98186.0 ± 115
SecondaryPart 2: Terminal Half-Life (t1/2) of PF-07817883 on Day 10

t1/2 of PF-07817883 was reported in this outcome measure. t1/2 was calculated by Loge(2)/kel, where kel was the terminal phase rate constant calculated by a linear regression of the log linear concentration-time curve. Only those data points judged to describe the terminal log-linear decline were used in the regression.

Time frame:
Day 10 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48 hours post-dose)
Reported as:
Mean · Hours
Part 2: Terminal Half-Life (t1/2) of PF-07817883 on Day 10
HoursPart 2: PF-07817883 200 mg (Suspension) BID, FastedPart 2: PF-07817883 600 mg (Suspension) BID, FastedPart 2: PF-07817883 1500 mg (Suspension) BID, FastedPart 2: PF-07817883 600 mg (Suspension) BID, Fasted, Chinese
Part 2: Terminal Half-Life (t1/2) of PF-07817883 on Day 1013.95 ± 9.393813.01 ± 8.856311.44 ± 6.83678.587 ± 5.8524
SecondaryPart 2: Amount Excreted in Urine as Unchanged Drug Over the Dosing Interval Tau (Aetau) of PF-07817883 on Day 10

Aetau was defined as amount excreted in urine as unchanged drug over the dosing interval tau, where tau= 12 hours. Aetau of PF-07817883 was reported in this outcome measure. Aetau was calculated as sum of (urine volume\*urine concentration) for each collection over the dosing interval.

Time frame:
Day 10 (0 to 12 hours)
Reported as:
Geometric mean · Milligram (mg)
Part 2: Amount Excreted in Urine as Unchanged Drug Over the Dosing Interval Tau (Aetau) of PF-07817883 on Day 10
Milligram (mg)Part 2: PF-07817883 200 mg (Suspension) BID, FastedPart 2: PF-07817883 600 mg (Suspension) BID, FastedPart 2: PF-07817883 1500 mg (Suspension) BID, FastedPart 2: PF-07817883 600 mg (Suspension) BID, Fasted, Chinese
Part 2: Amount Excreted in Urine as Unchanged Drug Over the Dosing Interval Tau (Aetau) of PF-07817883 on Day 1018.47 ± 1696.86 ± 5373.2 ± 1085.85 ± 20
SecondaryPart 2: Percent of Dose Excreted in Urine as Unchanged Drug Over the Dosing Interval Tau (Aetau%) of PF-07817883 on Day 10

Aetau% was defined as percentage of dose excreted in urine as unchanged drug over the dosing interval tau, where tau= 12 hours. Aetau% of PF-07817883 was reported in this outcome measure. Aetau% was calculated as 100\*Aetau/dose.

Time frame:
Day 10 (0 to 12 hours)
Reported as:
Geometric mean · Percentage of Dose Excreted
Part 2: Percent of Dose Excreted in Urine as Unchanged Drug Over the Dosing Interval Tau (Aetau%) of PF-07817883 on Day 10
Percentage of Dose ExcretedPart 2: PF-07817883 200 mg (Suspension) BID, FastedPart 2: PF-07817883 600 mg (Suspension) BID, FastedPart 2: PF-07817883 1500 mg (Suspension) BID, FastedPart 2: PF-07817883 600 mg (Suspension) BID, Fasted, Chinese
Part 2: Percent of Dose Excreted in Urine as Unchanged Drug Over the Dosing Interval Tau (Aetau%) of PF-07817883 on Day 109.261 ± 1616.15 ± 524.90 ± 1014.34 ± 20
SecondaryPart 2: Renal Clearance (CLr) of PF-07817883 on Day 10

CLr of PF-07817883 was reported in this outcome measure. CLr was calculated as Aetau/AUCtau.

Time frame:
Day 10 (0 to 12 hours)
Reported as:
Geometric mean · Liter/hour (L/hr)
Part 2: Renal Clearance (CLr) of PF-07817883 on Day 10
Liter/hour (L/hr)Part 2: PF-07817883 200 mg (Suspension) BID, FastedPart 2: PF-07817883 600 mg (Suspension) BID, FastedPart 2: PF-07817883 1500 mg (Suspension) BID, FastedPart 2: PF-07817883 600 mg (Suspension) BID, Fasted, Chinese
Part 2: Renal Clearance (CLr) of PF-07817883 on Day 101.074 ± 202.771 ± 53.586 ± 262.477 ± 51
SecondaryPart 3: Ratio Based on AUClast and AUCinf of Tablet Formulation Under Fed Condition and Fasted Condition

Data for AUClast and AUCinf are reported in the descriptive section. AUClast was calculated by the linear/log trapezoidal method. AUCinf was calculated as AUClast + (Clast/kel), where Clast was the predicted plasma concentration at the last quantifiable time point from the log-linear regression analysis. Ratio based on AUClast and AUCinf of tablet formulations under fed and fasted conditions were reported in statistical analysis.

Time frame:
Day 1 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48 hours post-dose)
Reported as:
Geometric mean · Nanogram*Hour per milliliter (ng*hr/mL)
Part 3: Ratio Based on AUClast and AUCinf of Tablet Formulation Under Fed Condition and Fasted Condition
Nanogram*Hour per milliliter (ng*hr/mL)Part 3: PF-07817883 SDD 600 mg (Tablet), FastedPart 3: PF-07817883 SDD 600 mg (Tablet), FedPart 3: PF-07817883 Crystalline 600 mg (Tablet), FastedPart 3: PF-07817883 Crystalline 600 mg (Tablet), Fed
AUCinf44140 ± 3828430 ± 2842930 ± 4346170 ± 27
AUClast43570 ± 3727750 ± 2941620 ± 4135930 ± 54
Statistical analysis
  • Part 3: PF-07817883 Crystalline 600 mg (Tablet), Fasted vs Part 3: PF-07817883 Crystalline 600 mg (Tablet), Fed · Ratio of adjusted geometric means: 72.87 · 90% CI 60.98 to 87.09A paired t-test was used. Values had been back-transformed from natural log scale. Ratios (and 90% CIs) were expressed as percentages
  • Part 3: PF-07817883 SDD 600 mg (Tablet), Fasted vs Part 3: PF-07817883 SDD 600 mg (Tablet), Fed · Ratio of adjusted geometric means: 76.45 · 90% CI 68.35 to 85.52A paired t-test was used. Values had been back-transformed from natural log scale. Ratios (and 90% CIs) were expressed as percentages
  • Part 3: PF-07817883 SDD 600 mg (Tablet), Fasted vs Part 3: PF-07817883 SDD 600 mg (Tablet), Fed · Ratio of adjusted geometric means: 73.52 · 90% CI 65.70 to 82.27A paired t-test was used. Values had been back-transformed from natural log scale. Ratios (and 90% CIs) were expressed as percentages
  • Part 3: PF-07817883 SDD 600 mg (Tablet), Fasted vs Part 3: PF-07817883 SDD 600 mg (Tablet), Fed · Ratio of adjusted geometric means: 75.16 · 90% CI 66.36 to 85.13A paired t-test was used. Values had been back-transformed from natural log scale. Ratios (and 90% CIs) were expressed as percentages
SecondaryPart 3: Ratio Based on Maximum Observed Concentration (Cmax) of Tablet Formulation Under Fed Condition and Fasted Condition

Data for Cmax are reported in the descriptive section. Ratio based on Cmax of tablet formulation under fed and fasted conditions were reported in statistical analysis.

Time frame:
Day 1 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48 hours post-dose)
Reported as:
Geometric mean · Nanogram per milliliter (ng/mL)
Part 3: Ratio Based on Maximum Observed Concentration (Cmax) of Tablet Formulation Under Fed Condition and Fasted Condition
Nanogram per milliliter (ng/mL)Part 3: PF-07817883 SDD 600 mg (Tablet), FastedPart 3: PF-07817883 SDD 600 mg (Tablet), FedPart 3: PF-07817883 Crystalline 600 mg (Tablet), FastedPart 3: PF-07817883 Crystalline 600 mg (Tablet), Fed
Part 3: Ratio Based on Maximum Observed Concentration (Cmax) of Tablet Formulation Under Fed Condition and Fasted Condition6934 ± 354590 ± 216284 ± 385008 ± 47
Statistical analysis
  • Part 3: PF-07817883 Crystalline 600 mg (Tablet), Fasted vs Part 3: PF-07817883 Crystalline 600 mg (Tablet), Fed · Ratio of adjusted geometric means: 76.72 · 90% CI 60.21 to 97.75A paired t-test was used. Values had been back-transformed from natural log scale. Ratios (and 90% CIs) were expressed as percentages
  • Part 3: PF-07817883 SDD 600 mg (Tablet), Fasted vs Part 3: PF-07817883 SDD 600 mg (Tablet), Fed · Ratio of adjusted geometric means: 70.92 · 90% CI 53.70 to 93.67A paired t-test was used. Values had been back-transformed from natural log scale. Ratios (and 90% CIs) were expressed as percentages
SecondaryPart 3: Time for Cmax (Tmax) of PF-07817883

Tmax of PF-07817883 was reported in this outcome measure.

Time frame:
Day 1 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48 hours post-dose)
Reported as:
Median · Hours
Part 3: Time for Cmax (Tmax) of PF-07817883
HoursPart 3: PF-07817883 600 mg (Suspension), FastedPart 3: PF-07817883 SDD 600 mg (Tablet), FastedPart 3: PF-07817883 SDD 600 mg (Tablet), FedPart 3: PF-07817883 Crystalline 600 mg (Tablet), FastedPart 3: PF-07817883 Crystalline 600 mg (Tablet), Fed
Part 3: Time for Cmax (Tmax) of PF-078178830.750 (0.500 to 1.05)1.01 (0.500 to 2.00)4.00 (1.00 to 4.00)1.34 (1.00 to 2.00)4.00 (2.00 to 6.00)
SecondaryPart 3: Maximum Observed Concentration (Cmax) of PF-07817883

Cmax of PF-07817883 was reported in this outcome measure.

Time frame:
Day 1 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48 hours post-dose)
Reported as:
Geometric mean · Nanogram/milliliter (ng/mL)
Part 3: Maximum Observed Concentration (Cmax) of PF-07817883
Nanogram/milliliter (ng/mL)Part 3: PF-07817883 600 mg (Suspension), FastedPart 3: PF-07817883 SDD 600 mg (Tablet), FastedPart 3: PF-07817883 SDD 600 mg (Tablet), FedPart 3: PF-07817883 Crystalline 600 mg (Tablet), FastedPart 3: PF-07817883 Crystalline 600 mg (Tablet), Fed
Part 3: Maximum Observed Concentration (Cmax) of PF-078178839354 ± 186934 ± 354590 ± 216284 ± 385008 ± 47
SecondaryPart 3: Area Under Plasma Concentration Time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of PF-07817883

AUClast of PF-07817883 was reported in this outcome measure. AUClast was calculated by the linear/log trapezoidal method.

Time frame:
Day 1 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48 hours post-dose)
Reported as:
Geometric mean · Nanogram*hour/milliliter (ng*hr/mL)
Part 3: Area Under Plasma Concentration Time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of PF-07817883
Nanogram*hour/milliliter (ng*hr/mL)Part 3: PF-07817883 600 mg (Suspension), FastedPart 3: PF-07817883 SDD 600 mg (Tablet), FastedPart 3: PF-07817883 SDD 600 mg (Tablet), FedPart 3: PF-07817883 Crystalline 600 mg (Tablet), FastedPart 3: PF-07817883 Crystalline 600 mg (Tablet), Fed
Part 3: Area Under Plasma Concentration Time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of PF-0781788342540 ± 3543570 ± 3727750 ± 2941620 ± 4135930 ± 54
SecondaryPart 3: Area Under the Concentration -Time Curve From Time Zero (0) Extrapolated to Infinite Time (AUCinf) of PF-07817883

AUCinf of PF-07817883 was reported in this outcome measure. AUCinf was calculated as AUClast + (Clast/kel), where Clast was the predicted plasma concentration at the last quantifiable time point from the log-linear regression analysis.

Time frame:
Day 1 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48 hours post-dose)
Reported as:
Geometric mean · Nanogram*hour/milliliter (ng*hr/mL)
Part 3: Area Under the Concentration -Time Curve From Time Zero (0) Extrapolated to Infinite Time (AUCinf) of PF-07817883
Nanogram*hour/milliliter (ng*hr/mL)Part 3: PF-07817883 600 mg (Suspension), FastedPart 3: PF-07817883 SDD 600 mg (Tablet), FastedPart 3: PF-07817883 SDD 600 mg (Tablet), FedPart 3: PF-07817883 Crystalline 600 mg (Tablet), FastedPart 3: PF-07817883 Crystalline 600 mg (Tablet), Fed
Part 3: Area Under the Concentration -Time Curve From Time Zero (0) Extrapolated to Infinite Time (AUCinf) of PF-0781788342970 ± 3544140 ± 3828430 ± 2842930 ± 4346170 ± 27
SecondaryPart 3: Terminal Half-Life (t1/2) of PF-07817883

t1/2 of PF-07817883 was reported in this outcome measure. t1/2 was calculated by Loge(2)/kel, where kel was the terminal phase rate constant calculated by a linear regression of the log linear concentration-time curve. Only those data points judged to describe the terminal log-linear decline were used in the regression.

Time frame:
Day 1 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48 hours post-dose)
Reported as:
Mean · Hours
Part 3: Terminal Half-Life (t1/2) of PF-07817883
HoursPart 3: PF-07817883 600 mg (Suspension), FastedPart 3: PF-07817883 SDD 600 mg (Tablet), FastedPart 3: PF-07817883 SDD 600 mg (Tablet), FedPart 3: PF-07817883 Crystalline 600 mg (Tablet), FastedPart 3: PF-07817883 Crystalline 600 mg (Tablet), Fed
Part 3: Terminal Half-Life (t1/2) of PF-078178837.578 ± 3.25367.957 ± 3.874010.15 ± 2.28906.822 ± 3.596411.07 ± 4.4518
SecondaryPart 3: Apparent Clearance (CL/F) of PF-07817883

CL/F of PF-07817883 was reported in this outcome measure. CL/F was calculated as dose/AUCinf.

Time frame:
Day 1 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48 hours post-dose)
Reported as:
Geometric mean · Liter/hour
Part 3: Apparent Clearance (CL/F) of PF-07817883
Liter/hourPart 3: PF-07817883 600 mg (Suspension), FastedPart 3: PF-07817883 SDD 600 mg (Tablet), FastedPart 3: PF-07817883 SDD 600 mg (Tablet), FedPart 3: PF-07817883 Crystalline 600 mg (Tablet), FastedPart 3: PF-07817883 Crystalline 600 mg (Tablet), Fed
Part 3: Apparent Clearance (CL/F) of PF-0781788313.97 ± 3513.58 ± 3821.09 ± 2813.98 ± 4312.98 ± 27
SecondaryPart 3: Apparent Volume of Distribution (Vz/F) of PF-07817883

Vz/F of PF-07817883 was reported in this outcome measure. Vz/F was calculated as dose/(AUCtau\*kel).

Time frame:
Day 1 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48 hours post-dose)
Reported as:
Geometric mean · Liter
Part 3: Apparent Volume of Distribution (Vz/F) of PF-07817883
LiterPart 3: PF-07817883 600 mg (Suspension), FastedPart 3: PF-07817883 SDD 600 mg (Tablet), FastedPart 3: PF-07817883 SDD 600 mg (Tablet), FedPart 3: PF-07817883 Crystalline 600 mg (Tablet), FastedPart 3: PF-07817883 Crystalline 600 mg (Tablet), Fed
Part 3: Apparent Volume of Distribution (Vz/F) of PF-07817883136.2 ± 55136.7 ± 50302.2 ± 31120.7 ± 55192.8 ± 64
SecondaryPart 3: Number of Participants With TEAEs

An AE was any untoward medical occurrence in a participant temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE was considered a TEAE if the event started during the effective duration of treatment. All events that started on or after the first dosing day and time/start time, if collected, but before the end of the study were considered as TEAEs.

Time frame:
From start of study treatment up to 29-36 days after administration of last dose of study intervention (maximum up to 49 days)
Reported as:
Count of participants · Participants
Part 3: Number of Participants With TEAEs
ParticipantsPart 3: PF-07817883 600 mg (Suspension), FastedPart 3: PF-07817883 SDD 600 mg (Tablet), FastedPart 3: PF-07817883 SDD 600 mg (Tablet), FedPart 3: PF-07817883 Crystalline 600 mg (Tablet), FastedPart 3: PF-07817883 Crystalline 600 mg (Tablet), Fed
Part 3: Number of Participants With TEAEs41142
SecondaryPart 3: Number of Participants With Laboratory Test Abnormalities

Laboratory parameters included: hematology (monocytes/leukocytes \>1.2\*ULN \[%\], partial thromboplastin time \>1.1\*ULN \[seconds\]) and urinalysis (urine hemoglobin \>=1, bacteria \>20 \[/lpf\]). Number of participants with any lab test abnormalities meeting the pre-specified criteria are reported in this outcome measure.

Time frame:
From start of study treatment up to 29-36 days after administration of last dose of study intervention (maximum up to 49 days)
Reported as:
Count of participants · Participants
Part 3: Number of Participants With Laboratory Test Abnormalities
ParticipantsPart 3: PF-07817883 600 mg (Suspension), FastedPart 3: PF-07817883 SDD 600 mg (Tablet), FastedPart 3: PF-07817883 SDD 600 mg (Tablet), FedPart 3: PF-07817883 Crystalline 600 mg (Tablet), FastedPart 3: PF-07817883 Crystalline 600 mg (Tablet), Fed
Part 3: Number of Participants With Laboratory Test Abnormalities00202
SecondaryPart 3: Number of Participants With Vital Signs Meeting Pre-Defined Criteria

Vital signs including SBP, DBP and PR were measured in a supine position after approximately 5 minutes of rest for the participant. Criteria for vital signs included: SBP: value \< 90 mmHg, change \>= 30 mmHg increase, change \>= 30 mmHg decrease; DBP: value \< 50 mmHg, change \>= 20 mmHg increase, change \>= 20 mmHg decrease; PR: value \< 40 bpm, value \> 120 bpm. 4. Number of participants with vital signs meeting any of the pre-defined criteria is reported in this outcome measure.

Time frame:
Up to Day 3 of each period
Reported as:
Count of participants · Participants
Part 3: Number of Participants With Vital Signs Meeting Pre-Defined Criteria
ParticipantsPart 3: PF-07817883 600 mg (Suspension), FastedPart 3: PF-07817883 SDD 600 mg (Tablet), FastedPart 3: PF-07817883 SDD 600 mg (Tablet), FedPart 3: PF-07817883 Crystalline 600 mg (Tablet), FastedPart 3: PF-07817883 Crystalline 600 mg (Tablet), Fed
Part 3: Number of Participants With Vital Signs Meeting Pre-Defined Criteria00000
SecondaryPart 3: Number of Participants With ECG Abnormalities

Standard 12 lead ECGs were obtained with the participant in a supine position after at least 5 minutes of rest using an ECG machine that automatically calculated the heart rate and measured PR interval, QT interval, QTcF and QRS complex. Number of participants with abnormalities in ECG were reported in this outcome measure.

Time frame:
Up to Day 3 of each period
Reported as:
Count of participants · Participants
Part 3: Number of Participants With ECG Abnormalities
ParticipantsPart 3: PF-07817883 600 mg (Suspension), FastedPart 3: PF-07817883 SDD 600 mg (Tablet), FastedPart 3: PF-07817883 SDD 600 mg (Tablet), FedPart 3: PF-07817883 Crystalline 600 mg (Tablet), FastedPart 3: PF-07817883 Crystalline 600 mg (Tablet), Fed
Part 3: Number of Participants With ECG Abnormalities00000
SecondaryPart 4: Time for Cmax (Tmax) of PF-07817883

Tmax of PF-07817883 was reported in this outcome measure.

Time frame:
Day 1 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48, 72 hours post-dose)
Reported as:
Median · Hours
Part 4: Time for Cmax (Tmax) of PF-07817883
HoursPart 4: PF-07817883 600 mg (Suspension), Fasted
Part 4: Time for Cmax (Tmax) of PF-078178830.500 (0.500 to 2.00)
SecondaryPart 4: Maximum Observed Concentration (Cmax) of PF-07817883

Cmax of PF-07817883 was reported in this outcome measure.

Time frame:
Day 1 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48, 72 hours post-dose)
Reported as:
Geometric mean · Nanogram/milliliter (ng/mL)
Part 4: Maximum Observed Concentration (Cmax) of PF-07817883
Nanogram/milliliter (ng/mL)Part 4: PF-07817883 600 mg (Suspension), Fasted
Part 4: Maximum Observed Concentration (Cmax) of PF-078178836791 ± 35
SecondaryPart 4: Area Under Plasma Concentration Time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of PF-07817883

AUClast of PF-07817883 was reported in this outcome measure. AUClast was calculated by the linear/log trapezoidal method.

Time frame:
Day 1 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48, 72 hours post-dose)
Reported as:
Geometric mean · Nanogram*hour/milliliter (ng*hr/mL)
Part 4: Area Under Plasma Concentration Time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of PF-07817883
Nanogram*hour/milliliter (ng*hr/mL)Part 4: PF-07817883 600 mg (Suspension), Fasted
Part 4: Area Under Plasma Concentration Time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of PF-0781788335520 ± 24
SecondaryPart 4: Area Under the Concentration -Time Curve From Time Zero (0) Extrapolated to Infinite Time (AUCinf) of PF-07817883

AUCinf of PF-07817883 was reported in this outcome measure. AUCinf was calculated as AUClast + (Clast/kel), where Clast was the predicted plasma concentration at the last quantifiable time point from the log-linear regression analysis.

Time frame:
Day 1 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48, 72 hours post-dose)
Reported as:
Geometric mean · Nanogram*hour/milliliter (ng*hr/mL)
Part 4: Area Under the Concentration -Time Curve From Time Zero (0) Extrapolated to Infinite Time (AUCinf) of PF-07817883
Nanogram*hour/milliliter (ng*hr/mL)Part 4: PF-07817883 600 mg (Suspension), Fasted
Part 4: Area Under the Concentration -Time Curve From Time Zero (0) Extrapolated to Infinite Time (AUCinf) of PF-0781788336910 ± 26
SecondaryPart 4: Terminal Half-Life (t1/2) of PF-07817883

t1/2 of PF-07817883 was reported in this outcome measure. t1/2 was calculated by Loge(2)/kel, where kel was the terminal phase rate constant calculated by a linear regression of the log linear concentration-time curve. Only those data points judged to describe the terminal log-linear decline were used in the regression.

Time frame:
Day 1 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48, 72 hours post-dose)
Reported as:
Mean · Hours
Part 4: Terminal Half-Life (t1/2) of PF-07817883
HoursPart 4: PF-07817883 600 mg (Suspension), Fasted
Part 4: Terminal Half-Life (t1/2) of PF-078178836.882 ± 3.0621
SecondaryPart 4: Apparent Clearance (CL/F) of PF-07817883

CL/F of PF-07817883 was reported in this outcome measure. CL/F was calculated as dose/AUCinf.

Time frame:
Day 1 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48, 72 hours post-dose)
Reported as:
Geometric mean · Liter/hour
Part 4: Apparent Clearance (CL/F) of PF-07817883
Liter/hourPart 4: PF-07817883 600 mg (Suspension), Fasted
Part 4: Apparent Clearance (CL/F) of PF-0781788316.26 ± 26
SecondaryPart 4: Apparent Volume of Distribution (Vz/F) of PF-07817883

Vz/F of PF-07817883 was reported in this outcome measure. Vz/F was calculated as dose/(AUCtau\*kel).

Time frame:
Day 1 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48, 72 hours post-dose)
Reported as:
Geometric mean · Liter
Part 4: Apparent Volume of Distribution (Vz/F) of PF-07817883
LiterPart 4: PF-07817883 600 mg (Suspension), Fasted
Part 4: Apparent Volume of Distribution (Vz/F) of PF-07817883146.7 ± 36
SecondaryPart 4: Number of Participants With TEAEs

An AE was any untoward medical occurrence in a participant temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE was considered a TEAE if the event started during the effective duration of treatment. All events that started on or after the first dosing day and time/start time, if collected, but before the end of the study were considered as TEAEs.

Time frame:
From start of study treatment up to 29-36 days after administration of last dose of study intervention (maximum up to 47 days)
Reported as:
Count of participants · Participants
Part 4: Number of Participants With TEAEs
ParticipantsPart 4: PF-07817883 600 mg (Suspension), Fasted
Part 4: Number of Participants With TEAEs4
SecondaryPart 4: Number of Participants With Laboratory Test Abnormalities

Laboratory parameters included: hematology (mean corpuscular volume \<0.9\*LLN \[cubic micrometer {um\^3}\], mean corpuscular hemoglobin \<0.9\*LLN \[picograms per cell {pg/cell}\], monocytes/leukocytes \>1.2\*ULN \[%\]). Number of participants with any lab test abnormalities meeting the pre-specified criteria are reported in this outcome measure.

Time frame:
From start of study treatment up to 29-36 days after administration of last dose of study intervention (maximum up to 47 days)
Reported as:
Count of participants · Participants
Part 4: Number of Participants With Laboratory Test Abnormalities
ParticipantsPart 4: PF-07817883 600 mg (Suspension), Fasted
Part 4: Number of Participants With Laboratory Test Abnormalities1
SecondaryPart 4: Number of Participants With Vital Signs Meeting Pre-Defined Criteria

Vital signs including SBP, DBP and PR were measured in a supine position after approximately 5 minutes of rest for the participant. Criteria for vital signs included: SBP: value \< 90 mmHg, change \>= 30 mmHg increase, change \>= 30 mmHg decrease; DBP: value \< 50 mmHg, change \>= 20 mmHg increase, change \>= 20 mmHg decrease; PR: value \< 40 bpm, value \> 120 bpm.

Time frame:
Up to Day 11
Reported as:
Count of participants · Participants
Part 4: Number of Participants With Vital Signs Meeting Pre-Defined Criteria
ParticipantsPart 4: PF-07817883 600 mg (Suspension), Fasted
SBP value < 90 mmHg1
SBP change >= 30 mmHg increase0
SBP change >= 30 mmHg decrease0
DBP value < 50 mmHg1
DBP change >= 20 mmHg increase0
DBP change >= 20 mmHg decrease0
Pulse rate value < 40 bpm0
Pulse rate value > 120 bpm0
SecondaryPart 4: Number of Participants With ECG Abnormalities

Standard 12 lead ECGs were obtained with the participant in a supine position after at least 5 minutes of rest using an ECG machine that automatically calculated the heart rate and measured PR interval, QT interval, QTcF and QRS complex. Number of participants with abnormalities in ECG were reported in this outcome measure.

Time frame:
Up to Day 11
Reported as:
Count of participants · Participants
Part 4: Number of Participants With ECG Abnormalities
ParticipantsPart 4: PF-07817883 600 mg (Suspension), Fasted
Part 4: Number of Participants With ECG Abnormalities0
SecondaryPart 5: Number of Participants With TEAEs

An AE was any untoward medical occurrence in a participant temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE was considered a TEAE if the event started during the effective duration of treatment. All events that started on or after the first dosing day and time/start time, if collected, but before the end of the study were considered as TEAEs.

Time frame:
From start of study treatment up to 38-45 days after administration of last dose of study intervention (maximum up to 65 days)
Reported as:
Count of participants · Participants
Part 5: Number of Participants With TEAEs
ParticipantsPF-07817883 600 mg (Suspension) BID/ Midazolam 5 mgMidazolam 5 mg
Part 5: Number of Participants With TEAEs1110
SecondaryPart 5: Number of Participants With Laboratory Test Abnormalities

Laboratory parameters included: hematology (lymphocytes \<0.8\*LLN \[10\^3/mm3\], lymphocytes/leukocytes \<0.8\*LLN \[%\], neutrophils/leukocytes \<0.8\*LLN \[%\], monocytes/leukocytes \>1.2\*ULN \[%\]), chemistry (amylase \>1.5\*ULN \[units/liter\] {U/L}), and urinalysis (urine hemoglobin \>=1). Number of participants with any lab test abnormalities meeting the pre-specified criteria are reported in this outcome measure.

Time frame:
From start of study treatment up to 38-45 days after administration of last dose of study intervention (maximum up to 65 days)
Reported as:
Count of participants · Participants
Part 5: Number of Participants With Laboratory Test Abnormalities
ParticipantsPF-07817883 600 mg (Suspension) BID/ Midazolam 5 mgMidazolam 5 mg
Part 5: Number of Participants With Laboratory Test Abnormalities52
SecondaryPart 5: Number of Participants With Vital Signs Meeting Pre-Defined Criteria

Vital signs including SBP, DBP and PR were measured in a supine position after approximately 5 minutes of rest for the participant. Criteria for vital signs included: SBP: value \< 90 mmHg, change \>= 30 mmHg increase, change \>= 30 mmHg decrease; DBP: value \< 50 mmHg, change \>= 20 mmHg increase, change \>= 20 mmHg decrease; PR: value \< 40 bpm, value \> 120 bpm.

Time frame:
From start of study treatment up to 38-45 days after administration of last dose of study intervention (maximum up to 65 days)
Reported as:
Count of participants · Participants
Part 5: Number of Participants With Vital Signs Meeting Pre-Defined Criteria
ParticipantsPF-07817883 600 mg (Suspension) BID/ Midazolam 5 mgMidazolam 5 mg
SBP value < 90 mmHg33
SBP change >= 30 mmHg increase00
SBP change >= 30 mmHg decrease01
DBP value < 50 mmHg22
DBP change >= 20 mmHg increase00
DBP change >= 20 mmHg decrease00
Pulse rate value < 40 bpm00
Pulse rate value > 120 bpm00
SecondaryPart 5: Number of Participants With ECG Abnormalities

Standard 12 lead ECGs were obtained with the participant in a supine position after at least 5 minutes of rest using an ECG machine that automatically calculated the heart rate and measured PR interval, QT interval, QTcF and QRS complex. Number of participants with abnormalities in ECG were reported in this outcome measure.

Time frame:
From start of study treatment up to 38-45 days after administration of last dose of study intervention (maximum up to 65 days)
Reported as:
Count of participants · Participants
Part 5: Number of Participants With ECG Abnormalities
ParticipantsPF-07817883 600 mg (Suspension) BID/ Midazolam 5 mgMidazolam 5 mg
Part 5: Number of Participants With ECG Abnormalities00
SecondaryPart 5: Time for Cmax (Tmax) of Midazolam

Tmax of midazolam was reported in this outcome measure.

Time frame:
Day 1 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 36, 48 hours post-dose) for Midazolam 5 mg arm and Day 10 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 36, 48 hours post-dose) for PF-07817883 600 mg (Suspension) BID/ Midazolam 5 mg arm
Reported as:
Median · Hours
Part 5: Time for Cmax (Tmax) of Midazolam
HoursPF-07817883 600 mg (Suspension) BID/ Midazolam 5 mgMidazolam 5 mg
Part 5: Time for Cmax (Tmax) of Midazolam0.500 (0.500 to 1.12)0.500 (0.500 to 1.02)
SecondaryPart 5: Area Under Plasma Concentration Time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of Midazolam

AUClast of midazolam was reported in this outcome measure. AUClast was calculated by the linear/log trapezoidal method.

Time frame:
Day 1 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 36, 48 hours post-dose) for Midazolam 5 mg arm and Day 10 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 36, 48 hours post-dose) for PF-07817883 600 mg (Suspension) BID/ Midazolam 5 mg arm
Reported as:
Geometric mean · Nanogram*hour/milliliter (ng*hr/mL)
Part 5: Area Under Plasma Concentration Time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of Midazolam
Nanogram*hour/milliliter (ng*hr/mL)PF-07817883 600 mg (Suspension) BID/ Midazolam 5 mgMidazolam 5 mg
Part 5: Area Under Plasma Concentration Time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of Midazolam92.37 ± 2777.46 ± 32
SecondaryPart 5: Terminal Half-Life (t1/2) of Midazolam

t1/2 of midazolam was reported in this outcome measure. t1/2 was calculated by Loge(2)/kel, where kel was the terminal phase rate constant calculated by a linear regression of the log linear concentration-time curve. Only those data points judged to describe the terminal log-linear decline were used in the regression.

Time frame:
Day 1 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 36, 48 hours post-dose) for Midazolam 5 mg arm and Day 10 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 36, 48 hours post-dose) for PF-07817883 600 mg (Suspension) BID/ Midazolam 5 mg arm
Reported as:
Mean · Hours
Part 5: Terminal Half-Life (t1/2) of Midazolam
HoursPF-07817883 600 mg (Suspension) BID/ Midazolam 5 mgMidazolam 5 mg
Part 5: Terminal Half-Life (t1/2) of Midazolam6.589 ± 1.65666.923 ± 1.9185
SecondaryPart 5: Apparent Clearance (CL/F) of Midazolam

CL/F of midazolam was reported in this outcome measure. CL/F was calculated as dose/AUCinf.

Time frame:
Day 1 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 36, 48 hours post-dose) for Midazolam 5 mg arm and Day 10 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 36, 48 hours post-dose) for PF-07817883 600 mg (Suspension) BID/ Midazolam 5 mg arm
Reported as:
Geometric mean · Liter/hour
Part 5: Apparent Clearance (CL/F) of Midazolam
Liter/hourPF-07817883 600 mg (Suspension) BID/ Midazolam 5 mgMidazolam 5 mg
Part 5: Apparent Clearance (CL/F) of Midazolam53.02 ± 2662.60 ± 31
SecondaryPart 5: Apparent Volume of Distribution (Vz/F) of Midazolam

Vz/F of midazolam was reported in this outcome measure. Vz/F was calculated as dose/(AUCinf\*kel).

Time frame:
Day 1 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 36, 48 hours post-dose) for Midazolam 5 mg arm and Day 10 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 36, 48 hours post-dose) for PF-07817883 600 mg (Suspension) BID/ Midazolam 5 mg arm
Reported as:
Geometric mean · Liter
Part 5: Apparent Volume of Distribution (Vz/F) of Midazolam
LiterPF-07817883 600 mg (Suspension) BID/ Midazolam 5 mgMidazolam 5 mg
Part 5: Apparent Volume of Distribution (Vz/F) of Midazolam488.5 ± 44598.9 ± 45
SecondaryPart 6: Maximum Observed Concentration (Cmax) of PF-07817883

Cmax of PF-07817883 was reported in this outcome measure.

Time frame:
Day 1 (pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours post-dose)
Reported as:
Geometric mean · Nanogram/milliliter (ng/mL)
Part 6: Maximum Observed Concentration (Cmax) of PF-07817883
Nanogram/milliliter (ng/mL)PF-07817883 6000 mg (Suspension), Fasted
Part 6: Maximum Observed Concentration (Cmax) of PF-0781788353160 ± 21
SecondaryPart 6: Time for Cmax (Tmax) of PF-07817883

Tmax of PF-07817883 was reported in this outcome measure.

Time frame:
Day 1 (pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours post-dose)
Reported as:
Median · Hours
Part 6: Time for Cmax (Tmax) of PF-07817883
HoursPF-07817883 6000 mg (Suspension), Fasted
Part 6: Time for Cmax (Tmax) of PF-078178831.00 (0.567 to 1.50)
SecondaryPart 6: Area Under Plasma Concentration Time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of PF-07817883

AUClast of PF-07817883 was reported in this outcome measure. AUClast was calculated by the linear/log trapezoidal method.

Time frame:
Day 1 (pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours post-dose)
Reported as:
Geometric mean · Nanogram*hour/milliliter (ng*hr/mL)
Part 6: Area Under Plasma Concentration Time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of PF-07817883
Nanogram*hour/milliliter (ng*hr/mL)PF-07817883 6000 mg (Suspension), Fasted
Part 6: Area Under Plasma Concentration Time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of PF-07817883248300 ± 17
SecondaryPart 6: Area Under the Concentration -Time Curve From Time Zero (0) Extrapolated to Infinite Time (AUCinf) of PF-07817883

AUCinf of PF-07817883 was reported in this outcome measure. AUCinf was calculated as AUClast + (Clast/kel), where Clast was the predicted plasma concentration at the last quantifiable time point from the log-linear regression analysis.

Time frame:
Day 1 (pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours post-dose)
Reported as:
Geometric mean · Nanogram*hour/milliliter (ng*hr/mL)
Part 6: Area Under the Concentration -Time Curve From Time Zero (0) Extrapolated to Infinite Time (AUCinf) of PF-07817883
Nanogram*hour/milliliter (ng*hr/mL)PF-07817883 6000 mg (Suspension), Fasted
Part 6: Area Under the Concentration -Time Curve From Time Zero (0) Extrapolated to Infinite Time (AUCinf) of PF-07817883253000 ± 17
SecondaryPart 6: Terminal Half-Life (t1/2) of PF-07817883

t1/2 of PF-07817883 was reported in this outcome measure. t1/2 was calculated by Loge(2)/kel, where kel was the terminal phase rate constant calculated by a linear regression of the log linear concentration-time curve. Only those data points judged to describe the terminal log-linear decline were used in the regression.

Time frame:
Day 1 (pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours post-dose)
Reported as:
Mean · Hours
Part 6: Terminal Half-Life (t1/2) of PF-07817883
HoursPF-07817883 6000 mg (Suspension), Fasted
Part 6: Terminal Half-Life (t1/2) of PF-0781788312.64 ± 7.1787

Adverse events

Collected over Part 1 and Part 6: From start of study treatment up to 28-35 days after administration of last dose of study intervention (maximum up to 48 and 52 days respectively); Part 2 and Part 5: From start of study treatment up to 38-45 days after administration of last dose of study intervention (maximum up to 55 and 65 days respectively); Part 3 and Part 4: From start of study treatment up to 29-36 days after administration of last dose of study intervention (maximum up to 49 and 47 days respectively). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part 1: Placebo (Suspension), Fasted0/10 (0%)0/10 (0%)4/10 (40%)
Part 1: Placebo (Suspension), Fed0/2 (0%)0/2 (0%)1/2 (50%)
Part 1: PF-07817883 150 mg (Suspension), Fasted0/6 (0%)0/6 (0%)2/6 (33.3%)
Part 1: PF-07817883 500 mg (Suspension), Fasted0/6 (0%)0/6 (0%)1/6 (16.7%)
Part 1: PF-07817883 500 mg (Suspension), Fed0/4 (0%)0/4 (0%)0/4 (0%)
Part 1: PF-07817883 1500 mg (Suspension), Fasted0/6 (0%)0/6 (0%)3/6 (50%)
Part 1: PF-07817883 3000 mg (Suspension), Fasted0/5 (0%)0/5 (0%)0/5 (0%)
Part 1: PF-07817883 4000 mg (Suspension), Fasted0/5 (0%)0/5 (0%)1/5 (20%)
Part 2: Placebo (Suspension) BID, Fasted0/6 (0%)0/6 (0%)2/6 (33.3%)
Part 2: PF-07817883 200 mg (Suspension) BID, Fasted0/4 (0%)0/4 (0%)1/4 (25%)
Part 2: PF-07817883 600 mg (Suspension) BID, Fasted0/4 (0%)0/4 (0%)0/4 (0%)
Part 2: PF-07817883 1500 mg (Suspension) BID, Fasted0/4 (0%)0/4 (0%)2/4 (50%)
Part 2: Placebo (Suspension) BID, Fasted, Chinese0/1 (0%)0/1 (0%)0/1 (0%)
Part 2: PF-07817883 600 mg (Suspension) BID, Fasted, Chinese0/3 (0%)0/3 (0%)2/3 (66.7%)
Part 3: PF-07817883 600 mg (Suspension), Fasted0/12 (0%)0/12 (0%)4/12 (33.3%)
Part 3: PF-07817883 SDD 600 mg (Tablet), Fasted0/12 (0%)0/12 (0%)1/12 (8.3%)
Part 3: PF-07817883 SDD 600 mg (Tablet), Fed0/6 (0%)0/6 (0%)1/6 (16.7%)
Part 3: PF-07817883 Crystalline 600 mg (Tablet), Fasted0/12 (0%)0/12 (0%)4/12 (33.3%)
Part 3: PF-07817883 Crystalline 600 mg (Tablet), Fed0/6 (0%)0/6 (0%)2/6 (33.3%)
Part 4: PF-07817883 600 mg (Suspension), Fasted0/6 (0%)0/6 (0%)4/6 (66.7%)
Part 5: PF-07817883 600 mg (Suspension) BID/ Midazolam 5 mg0/13 (0%)0/13 (0%)11/13 (84.6%)
Part 5: Midazolam 5 mg0/13 (0%)0/13 (0%)10/13 (76.9%)
Part 6: Placebo (Suspension), Fasted0/23 (0%)0/23 (0%)0/23 (0%)
Part 6: PF-07817883 6000 mg (Suspension), Fasted0/23 (0%)0/23 (0%)0/23 (0%)
Part 6: Moxifloxacin 400 mg, Fasted0/24 (0%)0/24 (0%)0/24 (0%)
Most frequent other events
Showing 10 of 41
Most frequent other events
EventPart 1: Placebo (Suspension), FastedPart 1: Placebo (Suspension), FedPart 1: PF-07817883 150 mg (Suspension), FastedPart 1: PF-07817883 500 mg (Suspension), FastedPart 1: PF-07817883 500 mg (Suspension), FedPart 1: PF-07817883 1500 mg (Suspension), FastedPart 1: PF-07817883 3000 mg (Suspension), FastedPart 1: PF-07817883 4000 mg (Suspension), FastedPart 2: Placebo (Suspension) BID, FastedPart 2: PF-07817883 200 mg (Suspension) BID, FastedPart 2: PF-07817883 600 mg (Suspension) BID, FastedPart 2: PF-07817883 1500 mg (Suspension) BID, FastedPart 2: Placebo (Suspension) BID, Fasted, ChinesePart 2: PF-07817883 600 mg (Suspension) BID, Fasted, ChinesePart 3: PF-07817883 600 mg (Suspension), FastedPart 3: PF-07817883 SDD 600 mg (Tablet), FastedPart 3: PF-07817883 SDD 600 mg (Tablet), FedPart 3: PF-07817883 Crystalline 600 mg (Tablet), FastedPart 3: PF-07817883 Crystalline 600 mg (Tablet), FedPart 4: PF-07817883 600 mg (Suspension), FastedPart 5: PF-07817883 600 mg (Suspension) BID/ Midazolam 5 mgPart 5: Midazolam 5 mgPart 6: Placebo (Suspension), FastedPart 6: PF-07817883 6000 mg (Suspension), FastedPart 6: Moxifloxacin 400 mg, Fasted
SomnolenceNervous system disorders0/100/20/60/60/40/60/50/50/60/40/40/40/10/30/120/120/60/120/60/69/139/130/230/230/24
HaematomaVascular disorders0/100/20/60/60/40/60/50/50/60/40/40/40/12/30/120/120/60/120/60/60/130/130/230/230/24
Upper respiratory tract infectionInfections and infestations0/101/20/60/60/40/60/50/50/60/40/40/40/10/30/120/120/60/120/62/61/130/130/230/230/24
ConstipationGastrointestinal disorders2/100/20/61/60/42/60/50/50/60/40/40/40/10/30/121/120/61/120/60/60/130/130/230/230/24
DiarrheaGastrointestinal disorders0/100/20/60/60/42/60/50/50/60/40/40/40/10/30/120/120/60/120/60/61/130/130/230/230/24
Muscle spasmsMusculoskeletal and connective tissue disorders1/100/20/60/60/40/60/50/50/60/40/40/40/11/30/120/120/60/121/60/60/130/130/230/230/24
Defaecation urgencyGastrointestinal disorders0/100/20/60/60/40/60/50/50/60/40/40/40/11/30/120/120/60/120/60/60/130/130/230/230/24
VomitingGastrointestinal disorders0/100/20/60/60/40/60/50/50/60/40/40/40/11/30/120/120/60/120/60/60/130/130/230/230/24
HypoaesthesiaNervous system disorders0/100/20/60/60/40/60/50/50/60/40/40/40/11/30/120/120/60/120/60/60/130/130/230/230/24
GlossodyniaGastrointestinal disorders0/100/20/60/60/40/60/50/50/61/40/40/40/10/30/120/120/60/120/60/60/130/130/230/230/24

Baseline characteristics

Safety analysis set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention. Participants were analyzed according to the product they actually received.

Age, Customized
Age, Customized(Participants)P1: C1: Placebo,Fast/PF-07817883 1500mg,Fast/PF-07817883 4000mg, FastP1: C1: PF-07817883 150mg,Fast/Placebo,Fast/PF-07817883 4000mg,FastP1: C1: PF-07817883 150 mg,Fast/PF-07817883 1500mg,Fast/Placebo,FastP1: C1: PF-07817883 150 mg,Fast/PF-07817883 1500mg,Fast/PF-07817883 4000mg,FastP1: C2: Placebo,Fast/PF-07817883 3000mg,Fast/Placebo,FedP1: C2: PF-07817883 500mg,Fast/Placebo,Fast/PF-07817883 500mg,FedP1: C2: PF-07817883 500mg,Fast/PF-07817883 3000mg,Fast/PF-07817883 500mg,FedPart 2: Placebo (Suspension) BID, FastedPart 2: PF-07817883 200 mg (Suspension) BID, FastedPart 2: PF-07817883 600 mg (Suspension) BID, FastedPart 2: PF-07817883 1500 mg (Suspension) BID, FastedPart 2: Placebo (Suspension) BID, Fasted, ChinesePart 2: PF-07817883 600 mg (Suspension) BID, Fasted, ChinesePart 3: Treatment Sequence ABCDPart 3: Treatment Sequence BCADPart 3: Treatment Sequence CABDPart 3: Treatment Sequence BACEPart 3: Treatment Sequence ACBEPart 3: Treatment Sequence CBAEPart 4: PF-07817883 600 mg (Suspension), FastedPart 5: Treatment Sequence ABPart 5: Treatment Sequence BAPart 6: Treatment Sequence ABCPart 6: Treatment Sequence BCAPart 6: Treatment Sequence CABPart 6: Treatment Sequence BACPart 6: Treatment Sequence ACBPart 6: Treatment Sequence CBATotal
18-44 Years011211252420320112244334433464
45-60 Years211011212020002110023410011029
Not Disclosed00000000000100000000000000001
Sex/Gender, Customized
Sex/Gender, Customized(Participants)P1: C1: Placebo,Fast/PF-07817883 1500mg,Fast/PF-07817883 4000mg, FastP1: C1: PF-07817883 150mg,Fast/Placebo,Fast/PF-07817883 4000mg,FastP1: C1: PF-07817883 150 mg,Fast/PF-07817883 1500mg,Fast/Placebo,FastP1: C1: PF-07817883 150 mg,Fast/PF-07817883 1500mg,Fast/PF-07817883 4000mg,FastP1: C2: Placebo,Fast/PF-07817883 3000mg,Fast/Placebo,FedP1: C2: PF-07817883 500mg,Fast/Placebo,Fast/PF-07817883 500mg,FedP1: C2: PF-07817883 500mg,Fast/PF-07817883 3000mg,Fast/PF-07817883 500mg,FedPart 2: Placebo (Suspension) BID, FastedPart 2: PF-07817883 200 mg (Suspension) BID, FastedPart 2: PF-07817883 600 mg (Suspension) BID, FastedPart 2: PF-07817883 1500 mg (Suspension) BID, FastedPart 2: Placebo (Suspension) BID, Fasted, ChinesePart 2: PF-07817883 600 mg (Suspension) BID, Fasted, ChinesePart 3: Treatment Sequence ABCDPart 3: Treatment Sequence BCADPart 3: Treatment Sequence CABDPart 3: Treatment Sequence BACEPart 3: Treatment Sequence ACBEPart 3: Treatment Sequence CBAEPart 4: PF-07817883 600 mg (Suspension), FastedPart 5: Treatment Sequence ABPart 5: Treatment Sequence BAPart 6: Treatment Sequence ABCPart 6: Treatment Sequence BCAPart 6: Treatment Sequence CABPart 6: Treatment Sequence BACPart 6: Treatment Sequence ACBPart 6: Treatment Sequence CBATotal
Female101010100200010212002201110019
Male121212364240312010265543334474
Not Disclosed00000000000100000000000000001
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)P1: C1: Placebo,Fast/PF-07817883 1500mg,Fast/PF-07817883 4000mg, FastP1: C1: PF-07817883 150mg,Fast/Placebo,Fast/PF-07817883 4000mg,FastP1: C1: PF-07817883 150 mg,Fast/PF-07817883 1500mg,Fast/Placebo,FastP1: C1: PF-07817883 150 mg,Fast/PF-07817883 1500mg,Fast/PF-07817883 4000mg,FastP1: C2: Placebo,Fast/PF-07817883 3000mg,Fast/Placebo,FedP1: C2: PF-07817883 500mg,Fast/Placebo,Fast/PF-07817883 500mg,FedP1: C2: PF-07817883 500mg,Fast/PF-07817883 3000mg,Fast/PF-07817883 500mg,FedPart 2: Placebo (Suspension) BID, FastedPart 2: PF-07817883 200 mg (Suspension) BID, FastedPart 2: PF-07817883 600 mg (Suspension) BID, FastedPart 2: PF-07817883 1500 mg (Suspension) BID, FastedPart 2: Placebo (Suspension) BID, Fasted, ChinesePart 2: PF-07817883 600 mg (Suspension) BID, Fasted, ChinesePart 3: Treatment Sequence ABCDPart 3: Treatment Sequence BCADPart 3: Treatment Sequence CABDPart 3: Treatment Sequence BACEPart 3: Treatment Sequence ACBEPart 3: Treatment Sequence CBAEPart 4: PF-07817883 600 mg (Suspension), FastedPart 5: Treatment Sequence ABPart 5: Treatment Sequence BAPart 6: Treatment Sequence ABCPart 6: Treatment Sequence BCAPart 6: Treatment Sequence CABPart 6: Treatment Sequence BACPart 6: Treatment Sequence ACBPart 6: Treatment Sequence CBATotal
American Indian or Alaska Native00000000010000000000000100002
Asian000000000120300011012410101119
Black or African American111111213210010011112121130131
White111111241010012200133212213239
More than one race00000001000000000001000000002
Not Disclosed00000000000100000000000000001
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)P1: C1: Placebo,Fast/PF-07817883 1500mg,Fast/PF-07817883 4000mg, FastP1: C1: PF-07817883 150mg,Fast/Placebo,Fast/PF-07817883 4000mg,FastP1: C1: PF-07817883 150 mg,Fast/PF-07817883 1500mg,Fast/Placebo,FastP1: C1: PF-07817883 150 mg,Fast/PF-07817883 1500mg,Fast/PF-07817883 4000mg,FastP1: C2: Placebo,Fast/PF-07817883 3000mg,Fast/Placebo,FedP1: C2: PF-07817883 500mg,Fast/Placebo,Fast/PF-07817883 500mg,FedP1: C2: PF-07817883 500mg,Fast/PF-07817883 3000mg,Fast/PF-07817883 500mg,FedPart 2: Placebo (Suspension) BID, FastedPart 2: PF-07817883 200 mg (Suspension) BID, FastedPart 2: PF-07817883 600 mg (Suspension) BID, FastedPart 2: PF-07817883 1500 mg (Suspension) BID, FastedPart 2: Placebo (Suspension) BID, Fasted, ChinesePart 2: PF-07817883 600 mg (Suspension) BID, Fasted, ChinesePart 3: Treatment Sequence ABCDPart 3: Treatment Sequence BCADPart 3: Treatment Sequence CABDPart 3: Treatment Sequence BACEPart 3: Treatment Sequence ACBEPart 3: Treatment Sequence CBAEPart 4: PF-07817883 600 mg (Suspension), FastedPart 5: Treatment Sequence ABPart 5: Treatment Sequence BAPart 6: Treatment Sequence ABCPart 6: Treatment Sequence BCAPart 6: Treatment Sequence CABPart 6: Treatment Sequence BACPart 6: Treatment Sequence ACBPart 6: Treatment Sequence CBATotal
Hispanic or Latino111121142000000210013103222233
Not Hispanic or Latino111101322440322012254641222260
Not Disclosed00000000000100000000000000001
08

Study locations

2 sites
  • New Haven Clinical Research Unit
    New Haven, Connecticut 06511, United States
  • Pfizer Clinical Research Unit - Brussels
    Brussels, Bruxelles-capitale, Région DE B-1070, Belgium
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2022 to primary completion in Sep 2023, 10 months.

Results were first posted in Nov 2024, 1 year 2 months after primary completion.

Of 233 industry-sponsored phase 1 interventional studies under COVID-19, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 12. This study's 10 months is above that.

Counting every sponsor, half of 384 studies reached it within 7 months; a quarter within 3 and three quarters within 15.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 11, 2022
First posted
Oct 14, 2022
StartActual
Oct 17, 2022
Primary completionActual
Sep 15, 2023
CompletionActual
Sep 15, 2023
Results first posted
Nov 21, 2024
Last update
Nov 21, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 21, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05580003
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Oct 14, 2022
Start date
Oct 17, 2022
Primary completion
Sep 15, 2023
Completion
Sep 15, 2023
Results posted
Nov 21, 2024
Last update
Nov 21, 2024

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ibuzatrelvir · Midazolam

Start the discussion